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 ﻣﺴﺘﺨﻠﺺ
 
 ﻓﺎﻋﻠﻴﺔ ﺍﺜﻨﻰ ﻋﺸﺭ ﻨﺒﺎﺕ ﻁﺒﻲ ﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﺒﻜﺘﻴﺭﻴﺎ :ﺍﻟﻌﻨﻭﺍﻥ
  
  : ﻣﻘﺪﻣﺔ
ﻤﻘﺎﻭﻤﺔ ﺍﻟﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﻤﺘﺼﺎﻋﺩﺓ ﻟﻜل ﻤﻥ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺍﻟﺘﻘﻠﻴﺩﻴﺔ ﻭﺍﻟﺒﺩﻴﻠﺔ 
ﺍﻟﺼﻌﺏ ﻤﻌﺎﻟﺠﺔ ﺃﻤﺭ ﺍﻟﺠﺭﻭﺡ ﺍﻟﻤﻠﺘﻬﺒﺔ ﻭﺍﻟﺨﺭﺍﺠﺎﺕ ﻭﺍﻷﻤﺭﺍﺽ ﺍﻟﺨﻤﺠﻴﺔ ﻟﺫﺍ ﺠﻌﻠﺕ ﻤﻥ 
ﻜﺎﻥ ﻫﺩﻑ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻭ ﺇﻴﺠﺎﺩ ﻤﻀﺎﺩﺍﺕ ﺤﻴﻭﻴﺔ ﻤﺴﺘﺨﻠﺼﺔ ﻤﻥ ﺍﻟﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ ﺍﻟﺘﻲ 
 .ﺍﺴﺘﺨﺩﻤﺕ ﻵﻻﻑ ﺍﻟﺴﻨﻴﻴﻥ ﻓﻲ ﺍﻟﻁﺏ ﺍﻟﺸﻌﺒﻲ ﺍﻟﺴﻭﺩﺍﻨﻲ
  
  :اﻷهﺪاف
ﺼﻤﻤﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﻤﻌﺭﻓﺔ ﺤﺴﺎﺴﻴﺔ ﺨﻤﺴﺔ ﺃﻨﻭﺍﻉ ﺒﻜﺘﻴﺭﻴﺔ ﻤﻌﺯﻭل ﻤﻥ 
ﺍﻟﺠﺭﻭﺡ ﻭﺍﻟﺨﺭﺍﺠﺎﺕ ﻀﺩ ﻤﺴﺘﺨﻠﺼﺎﺕ ﺍﺜﻨﻰ ﻋﺸﺭ ﻨﺒﺎﺕ ﻁﺒﻲ ﻭﺍﻻﻨﻭﺍﻉ ﺍﻟﺒﻜﺘﻴﺭﻴﺔ ﻫﻲ 
ﺍﻷﺸﺭﻴﺸﻴﺔ ﺍﻟﻘﻭﻟﻭﻨﻴﺔ، ﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ ، ﺍﻟﺯﺍﺌﻔﺔ ﺍﻟﺯﻨﺠﺎﺭﻴﺔ ، ﺍﻟﻜﺒﺴﻴﻼ ﺍﻟﺭﺌﻭﻴﺔ 
ﻭﺍﻟﻤﺘﻘﻠﺒﺔ ﺍﻟﺭﺍﺌﻌﺔ ﺃﻤﺎ ﺍﻟﺨﻼﺼﺎﺕ ﻓﻘﺩ ﺃﺨﺫﺕ ﻤﻥ ﺍﻟﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ ﺍﻵﺘﻴﺔ ﺍﻟﻤﺭﻴﻤﻴﺔ ﻗﺸﺭ 
، ﺤﺏ ﺍﻟﻌﺭﻭﺱ، ﺍﻟﺫﺭﻴﺩﺓ، ﺍﻟﺤﻨﻭﺓ، ﺍﻟﻴﺴﺭ (ﻔﺼﺔﺍﻟﻌ)ﺍﻟﺭﻤﺎﻥ، ﻟﺏ ﺍﻟﺭﻤﺎﻥ، ﺍﻟﺜﻭﻴﺎ 
 .، ﺍﻟﻜﺭﻤﺩﻭﺩﺓ ﺍﻟﺤﻠﻴﻴﺕ، ﺍﻟﻔﻜﻬﺕ، ﻋﺭﻕ ﺍﻟﺤﺠﺭ ﻭﺍﻟﺼﺤﺏ( ﺍﻟﺭﻭﺍﻕ)
  
  :اﻟﻤﻮاد وﻃﺮق اﻟﺒﺤﺚ
ﺘﻘﻴﻴﻡ ﺤﺴﺎﺴﻴﺔ ﺍﻷﻨﻭﺍﻉ ﺍﻟﺒﻜﺘﻴﺭﻴﺔ ﺍﻟﻤﺨﺘﻠﻔﺔ ﺘﺠﺎﻩ ﻤﺴﺘﺨﻠﺼﺎﺕ ﺍﻟﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ 
ﻭﺴﻴﻠﺔ ﺍﻟﻤﺨﺘﺎﺭﺓ ﻴﻌﺘﻤﺩ ﻋﻠﻰ ﻭﺠﻭﺩ ﺤﻴﺯ ﻤﻥ ﺍﻟﺘﺜﺒﻴﻁ ﻭﻗﻴﺎﺱ ﻤﺤﻴﻁﺔ ﻭﺫﻟﻙ ﺍﻋﺘﻤﺎﺩﺍﹰ ﻋﻠﻰ 
  .ﺍﻻﻨﺘﺸﺎﺭ ﻓﻲ ﺍﻵﺠﺎﺭ
ﺤﺘﻰ ﺘﺘﻡ ﺍﻟﻤﻘﺎﺭﻨﺔ ﺘﻡ ﺍﺴﺘﻌﻤﺎل ﻜل ﻤﻥ ﺍﻟﺒﻜﺘﻴﺭﻴﺎ ﺍﻻﺨﺘﻴﺎﺭﻴﺔ ﺍﻷﺸﺭﻴﺘﻴﺔ ﺍﻟﻘﻭﻟﻭﻨﻴﺔ 
 CCTA)ﺍﻟﺯﺍﺌﻔﺔ ﺍﻟﺯﻨﺠﺎﺭﻴﺔ ( 32952CCTA)ﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ ( 229 52CCTA)
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ﻭﺃﻴﻀﺎﹰ ( 6328CTCN)ﻭﺍﻟﻌﻀﻭﻴﺔ ( 75653CCTA)، ﻜﻠﻴﺒﺴﻴﻼ ﺍﻟﺭﺌﻭﻴﺔ ( 35872
ﺔ ﺍﻟﺘﻘﻠﺩﻴﺔﻱ ﺍﻷﺘﻴﺔ ﺒﻨﺯﺍﻴل ﻴﻨﺴﻠﻴﻥ، ﺍﻴﺭﺜﺭﻭﻤﺎﻴﺴﻴﻥ، ﺍﺴﺘﻌﻤﻠﺕ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴ
 .ﺠﻴﻨﺘﺎﻤﺎﻴﺴﻴﻥ، ﻭﺴﻴﻔﺘﺭﺯﻭﻥ 
  
  :اﻟﻨﺘﺎﺋﺞ
ﺒﺎﺴﺘﻌﻤﺎل ﻁﺭﻕ ﺍﻟﺒﺤﺙ ﺍﻻﺨﺘﻴﺎﺭﻴﺔ ﺍﻟﻜﻴﻔﻴﺔ ﺘﻡ ﺍﻟﺘﻌﺭﻑ ﻋﻠﻰ ﺍﻟﻤﻜﻭﻨﺎﺕ ﺍﻟﻨﺒﺎﺘﻴﺔ 
ﺍﻟﻜﺒﻴﺭﺓ ﻟﺨﻼﺼﺎﺕ ﻜل ﻤﻥ ﺍﻷﺜﻨﻰ ﻋﺸﺭ ﻨﺒﺎﺕ ﻁﺒﻲ ﻭﻗﺩ ﺘﻡ ﺍﻴﺠﺎﺩ ﺍﻷﻋﺩﺍﺩ ﻭﺍﻟﻜﻤﻴﺎﺕ 
ﻴﺩﺍﺕ ﺍﻟﺼﺎﺒﻭﻨﻴﺎﺕ، ﺠﻠﻴﻜﻭﺴﻠﻴﺩﺍﺕ ﺍﻟﻘﻠﺒﻴﺔ، ﺍﻟﻤﺨﺘﻠﻔﺔ ﻟﻜل ﻤﻥ ﺍﻟﻌﺼﻴﺎﺕ ﺍﻟﻔﻼﻓﻨ
ﺠﻠﻴﻜﻭﺴﻴﺩﺍﺕ ﺍﻟﻔﻴﻨﻭﻟﻴﺔ ، ﺠﻠﻴﻜﻭﺴﻴﺩﺍﺕ ﺍﻷﻨﺜﺭﻜﻭﻨﻴﺔ، ﺠﻠﻴﻜﻭﺴﻴﺩﺍﺕ ﺍﻟﺴﻴﺎﻨﻭﺠﻴﻨﻴﺔ، 
  .ﻭﺍﻟﻘﻠﻭﻴﺩﺍﺕ
ﺘﻡ ﻋﺯل ﻤﺌﺔ ﻨﻭﻉ ﺒﻜﺘﻴﺭﻱ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻭﺴﺎﺌل ﺍﻻﺨﺘﺒﺎﺭﻴﺔ ﻭﻭﺠﺩ ﻋﻠﻰ ﺃﻨﻬﺎ ﺘﺘﻜﻭﻥ 
%( 02)ﺎﺭﻴﺔ ﺍﻟﺯﺍﺌﻔﺔ ﺍﻟﺯﻨﺠ%( 02)ﻤﻥ ﺒﻜﺘﻴﺭﻴﺎ ﺴﺎﻟﺒﺔ ﺍﻟﺠﺭﺍﻡ ﻓﻲ ﺍﻻﺸﺭﻴﺸﻴﺔ ﺍﻟﻘﻭﻟﻭﻨﻴﺔ 
ﻭﺒﻜﺘﻴﺭﻴﺎ ﻤﻭﺠﺒﺔ ﺍﻟﺠﺭﺍﻡ ﻫﻲ %(. 71)ﻜﻠﻴﺴﻴﻼ ﺍﻟﺭﺌﻭﻴﺔ %( 81)ﺍﻟﻤﺘﻘﻠﺒﺔ ﺍﻟﺭﺍﺌﻌﺔ 
ﻭﻫﻲ ﻨﺴﺒﺔ ﻤﻥ %( 7)ﻭﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻴﺜﺴﻠﻥ %( 81)ﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ 
  .ﺍﻻﻨﺘﺸﺎﺭ ﻴﺠﺏ ﺍﻻﻨﺘﺒﺎﻩ ﻟﻬﺎ
ﻤﻌﻅﻡ ﺨﻼﺼﺎﺕ ﺍﻟﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ ﺍﻟﺘﻲ ﺍﺴﺘﺨﻠﺼﺕ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻤﻴﺜﺎﻨﻭل ﺃﻅﻬﺭﺕ 
ﺔ ﻋﺎﻟﻴﺔ ﻀﺩ ﻜل ﻋﻥ ﺍﻻﺸﺭﻴﺸﻴﺔ ﺍﻟﻘﻭﻟﻭﻨﻴﺔ ﻭﺍﻟﺯﺍﺌﻔﺔ ﺍﻟﺯﻨﺠﺎﺭﻴﺔ ﻭﺍﻟﻤﺘﻘﻠﺒﺔ ﺍﻟﺭﺍﺌﻌﺔ ﺤﺴﺎﺴﻴ
ﻭﻜﻠﺴﻴﻼ ﺍﻟﺭﺌﻭﻴﺔ ﻭﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ ﻭﻗﺩ ﻭﺠﺩ ﻋﻠﻰ ﺃﻨﻬﺎ ﺃﻗﻭﻯ ﻤﻥ ﺘﻠﻙ ﺍﻟﺘﻲ ﺍﻟﺨﻼﺼﺎﺕ 
  .ﺍﻟﺘﻲ ﺍﺴﺘﺨﻠﺼﺕ ﺒﻭﺍﺴﻁﺔ ﺍﻟﺒﻨﺯﻴﻥ ﻭﺍﻟﻜﻠﻭﺭﻓﻭﺭﻡ
ﺫﻫﺒﻴﺔ ﻜل ﺨﻼﺼﺎﺕ ﺍﻟﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ ﺍﻟﻤﺨﺘﺒﺭﺓ ﺃﻅﻬﺭﺕ ﺤﺴﺎﺴﻴﺔ ﻀﺩ ﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟ
ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻴﺜﺴﻠﻥ ﻜﻤﺎ ﺃﻨﻪ ﻭﺠﺩ ﻋﻠﻰ ﺃﻥ ﻗﺸﺭ ﺍﻟﺭﻤﺎﻥ ﻴﺤﺘﻭﻱ ﺃﻗﻭﻯ ﺍﻟﻤﻀﺎﺩﺍﺕ 
 .ﺜﻡ ﺍﻟﺼﺤﺏ( ﺍﻟﻌﻔﺼﺔ)ﺍﻟﺒﻜﺘﻴﺭﻴﺔ ﻓﺎﻋﻠﻴﺔ ﻭﻴﻠﻴﻪ ﺍﻟﺘﻭﻴﺎ 
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  :اﻟﺨﻼﺻﺔ
ﺒﻭﺴﻴﻠﺔ ﺍﻟﺘﺨﻔﻴﻑ ﺃﻅﻬﺭﺕ ﺃﻗل ﺘﺭﻜﻴﺯ ﻤﺜﺒﻁ ( ﺍﻟﻌﻔﺼﺔ)ﻋﻨﺩ ﺍﺨﺘﺒﺎﺭ ﺨﻼﺼﺔ ﺍﻟﺜﻭﻴﺎ 
ﺼﺔ ﺃﻗﻭﻯ ﻤﻀﺎﺩ ﺒﻜﺘﻴﺭﻱ ﻀﺩ ﻜل ﺍﻷﻨﻭﺍﻉ ﺍﻟﺒﻜﺘﻴﺭﻴﺔ ﺍﻻﺨﺘﻴﺎﺭﻴﺔ، ﻟﺫﺍ ﺘﻌﺘﺒﺭ ﻫﺫﻩ ﺍﻟﺨﻼ
ﻭﺍﺴﻊ ﺍﻟﻤﺩﻯ ﺒﻴﻨﻤﺎ ﺃﻅﻬﺭﺕ ﺨﻼﺼﺔ ﻗﺸﺭ ﺍﻟﺭﻤﺎﻥ ﺃﻋﻠﻰ ﺘﺭﻜﻴﺯ ﻤﺜﺒﻁ ﻟﻠﺒﻜﺘﻴﺭﻴﺎ 
ﺍﻻﺨﺘﻴﺎﺭﻴﺔ ﻭﻗﺩ ﺘﻤﺕ ﻤﻼﺤﻅﺔ ﺃﻥ ﺍﻟﺒﻜﺘﻴﺭﻴﺎ ﺍﻟﻌﺼﻭﻴﺔ ﻫﻲ ﺍﻷﻜﺜﺭ ﺍﺴﺘﺠﺎﺒﺔ ﻟﺨﻼﺼﺎﺕ 
  .ﻜل ﻤﻥ ﺍﻟﺼﺤﺏ ، ﻗﺸﺭ ﺍﻟﺭﻤﺎﻥ ، ﺍﻟﺜﻭﻴﺎ
ﺍﻟﺜﻭﻴﺎ ﺍﻟﻔﺎﻋﻠﻴﺔ ﺍﻟﺠﻴﺩﺓ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺒﻜﺘﻴﺭﻴﺔ ﻟﺨﻼﺼﺎﺕ ﻜل ﻤﻥ ﻗﺸﺭ ﺍﻟﺭﻤﺎﻥ ﻭ
ﻭﺍﻟﺼﺤﺏ ﻀﺩ ﺍﻟﻌﻨﻘﻭﺩﻴﺔ ﺍﻟﺫﻫﺒﻴﺔ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻤﻴﺜﺴﻠﻥ ﺃﺒﺭﺯﺕ ﻗﻭﺘﻬﺎ ﻜﻤﺼﺩﺭ ﻟﺘﺤﺴﻴﻥ 
  .ﺍﻟﻌﻼﺝ ﻭﺇﻤﻜﺎﻨﻴﺔ ﺍﺠﺘﺜﺎﺜﻬﺎ ﻟﺫﺍ ﻭﺠﺏ ﺇﺠﺭﺍﺀ ﺍﻟﻤﺯﻴﺩ ﻤﻥ ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻋﻠﻴﻬﺎ
ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻭﻀﺤﺕ ﻤﺩﻯ ﺍﻟﺤﻭﺠﺔ ﻟﻤﺯﻴﺩ ﻤﻥ ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻋﻠﻰ ﺨﻼﺼﺎﺕ 
ﻟﻔﺎﻋﻠﻴﺔ ﻭﺃﻴﻀﺎﹰ ﺍﻟﺤﻭﺠﺔ ﺍﻟﻤﻴﺜﺎﻨﻭل ﻭﺍﻟﺘﻲ ﺘﺤﺩﻴﺩﺍﹰ ﻅﻬﺭﺕ ﻜﻤﻀﺎﺩﺍﺕ ﺒﻜﺘﻴﺭﻴﺔ ﺠﻴﺩﺓ ﺍ
ﻹﺠﺭﺍﺀ ﺍﺨﺘﺒﺎﺭﺍﺕ ﻋﻠﻰ ﺨﻼﺼﺎﺕ ﺍﻟﺒﻨﺯﻴﻥ ﻭﺍﻟﻜﻭﺭﻓﻭﺭﻡ ﻟﻠﻨﺒﺎﺘﺎﺕ ﺍﻟﻁﺒﻴﺔ ﺍﻟﻤﺨﺘﺒﺭﺓ 
  .ﻻﻜﺘﺸﺎﻑ ﻤﺩﻯ ﻓﺎﻋﻠﻴﺘﻬﺎ
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Abstract 
The ever growing bacterial resistance to both conventional and 
alternative antibiotics made it very difficult to manage infected wounds 
and abscesses and other infectious diseases. Hence, the aim of this 
study was to find antibacterial agents from a collection of medicinal 
plants that have been in use for thousands of years in Sudanese 
traditional medicine. 
This study was designed to evaluate the susceptibility of 5 bacterial 
species isolated from wounds and abscesses to extracts of 12 medicinal 
plants. The bacterial isolates were Escherichia coli, Staphylococcus 
aureus, Pseudomonas aeruginosa, Klebsiella sp and Proteus vulgaris; 
and the extracts were taken from Salvia orientalis,   Punicar granatum 
(Bark and Wood), Biota orientalis, Piper cubeba, Acorus calamus, 
Candula arvensis, Moringa perigrina, Nauclea lotifolia, Ferula 
asafoetida,   Cissus petiolata, and Petasites hybridus.  
The evaluation of bacterial susceptibility to the selected medicinal plants 
was based on the presence or absence of inhibition zone and zone 
diameter, using the cup plate agar diffusion method. 
For comparative reasons standard Escherichia coli (NCTC 25922); 
Staphylococcus aureus (NCTC 25923); Pseudomonas aeruginosa (NCTC 
27853); Klebsella sp (NCTC 35657); Bacillus subtilis (ATCC 8236), and 
conventional antibiotics including Benzylepenicillin, Erythromycin, 
Gentamycin and Ceftriaxone were used  
The major phytoconstituents in the extracts of the 12 medicinal plants 
were identified using standard qualitative methods. Varying numbers 
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and quantities of Tannins, Flavonoids, Saponins, Cardic glycoside, 
phenolic glycoside, Anthraquinone glycoside, Cyanogenic glycosides 
and Alkaloids were found. 
Adopting the standard methods, 100 bacterial organisms were isolated, 
and found to consist of Gram’s negative bacteria (Escherichia coli (20%); 
Pseudomonas aeruginosa (20%); Proteus vulgaris (18%) and Klebseilla 
sp. (17%); and Gram’s positive Staphylococcus aureus (18%); and 7% of 
Methicillin-resistant-Staphylococcus aureus (MRSA) which could be 
concidere as an alarming level of prevalence. 
Methanolic extracts of medicinal plants against bacterial isolates, high 
sensitivity was shown by: Escherichia coli, Pseudomonas aeruginosa, 
Proteus vulgaris, Klebsiella sp and Staphylococcus aureus to the 
majority of the test medicinal plants. This sensitivity was found to be 
more than that of the benzenic and chloroformic extracts. 
Methicillin-resistant Staphylococcus aureus (MRSA) has shown 
sensitivity to all tested medicinal plants extracts, however, Punicar 
granatum (Bark) gave the highest antibacterial activity followed by Biota 
orientalis and then Anogeissus leiocarpus. These results revealed the 
potentials of these plants as a source of effective antibacterial agents 
that can improve the treatment and possibly the eradication of MRSA 
Biota orientalis extracts when tested using agar plate dilution method, 
have shown the lowest MIC against all tested standard bacteria, hence it 
was considered as a potential wide-spectrum antibacterial medicinal 
plant extract. Whereas Punicar granatum (Bark) showed that it has the 
highest MIC. Also, it was observed that Bacillus subtilis is the most 
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susceptible to Anogeissus leiocarpus, Punicar granatum (Bark) and 
Biota orientalis. 
This study revealed the need for more studies on MRSA. Further studies 
are olso needed to explore the activity of benzinic and chloroformic 
extract of all test medicinal plants. The methanolic extract, especially 
those showing high antibacterial efficacy sould be subjected to rigorous 
testing to determine their usefulness as alternative antibacterial agents.
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1. Introduction and Literature Review 
1.1. Medicinal Plants: Past and Future  
Man has been using medicinal Plants as source of treatment for his 
ailments over the millennia. Therfore, a wealth of ethno-medical 
knowledge that was passed down from generation to generation through 
apprenticeship and clerkship has been made available today and 
awaiting extensive exploration. Moreover, this ethnopharmacological 
knowledge would reduce empiricism and increase the chance of 
success in new drug-finding efforts (Patwardhan, 2005; Cordell and 
Colvard, 2005). This can only be attained only if academia and research 
institutions had the full support of governments and regional and 
international organisations. Such support is vitally important due the 
ever diminishing interest of the pharmaceutical industry in natural 
products which is believed to be chemically complex and lacking 
assurance of renewable supplies.   
However, the limited studies that have been done so far, have already 
lead to discovery of various new active compounds (Runyoro 2006) of 
known therapeutic properties (Harborne and Baxter, 1995). The results 
of such studies indicated that the medicinal plants that our ancestors 
have used, could be an important source of new biologically active 
compounds that can be used for treating various diseases (Clardy and 
Walsh, 2004). Antimicrobial properties of various medicinal plants that 
can be used for treating infectous deseases have been reported (Nimri 
et al., 1999; Saxena and Sharma, 1999, Srinivasan, 2001).  
Even today medicinal plants are still being used to treat various diseases 
worldwide, especially in developing countries including Sudan, and in 
  
Page 13 of 219 
 
areas of limited access to modern medicines in particular, (Iwu et al., 
1999,). However, in the industrialised countries where full access to 
modern medicines is available to everybody, herbal remedies still 
continue to play a role in the cure of diseases (Tabuti et al., 2003). It is 
estimated that up to a quarter of all prescriptions contains one or more 
components of plants origin (Farnsworth1990), and about 50% of the 
modern drugs either contain plant materials or these materials have 
provided the model for them (Harbone, 1998). 
1.2. Mechanisms of control of diseases and 
wound by medicinal plants extracts 
Reactive oxygen species are involved in a number of degenerative 
diseases. It was found that delaying or preventing the onset of these 
diseases (arthrosclerosis, cancer, cirrhosis and diabetes) and in healing 
wounds (Aboutwerat et al., 2003) was attributed to plant antioxidants 
constituents such as tannins, lignans, stableness, coumarins, quinones, 
xanthones, phenolic acids, flavones, flavonols, catechins, anthocyanins 
and proanthocyanins. These diseases are caused by reactive oxygen 
species; therefore the redox properties of the antioxidant constituents 
allow them to act as hydrogen donors, reducing agents, hydroxyl 
radicals (OHÅ) or super-oxide radical (OÅ2) scavengers (Robards et al., 
1999; Govindarajan et al. 2005). In addition to that, they were found to 
act as strong chelators of metal ions (Rice-Evans et al. 1995). Therefore, 
it was concluded that consumption of antioxidants rich fruits and 
vegetables would control these diseases (Sun et al. 2002). 
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1.3. Wounds and Abscesses  
1.3.1. Wounds 
Wounds are a type of injury in which the skin is torn, cut or punctured (an 
open wound), or where blunt force trauma causes a contusion (a closed 
wound). In pathology, it specifically refers to a sharp injury which 
damages the dermis of the skin. 
The skin is home to a wide variety of bacteria that causes the host no 
problems when the skin is intact. However, when disrupted with a 
wound, the skin provides ideal conditions for bacteria to become 
pathogenic, multiply and ‘invade’ through that weak point. Wounds 
provide an ideal culture medium for the growth of bacteria because they 
have the optimum temperature for bacterial growth; a frequent supply of 
nutrients in the form of organic debris; and a moist environment. The 
presence of bacteria in a wound does not necessarily indicate that 
infection has occurred or leads to impairment of wound healing. 
However, increased bacterial load can lead to reduced or no healing 
(Dealey 1995; Collier 2001).  
Wounds being acute, post-operative or chronic such as pressure ulcers, 
leg ulcers and acute wounds that have been present for more than six 
weeks (Dealey 1995), can be classified depending on the amount of 
bacteria present and the type of pathogens likely to be present. The main 
types are: contaminated wounds (Bacteria are present in low numbers 
but there is no multiplication); colonised wounds (There is multiplication 
of bacteria but no host reaction.); infected wounds (There is deposition 
and multiplication of bacteria in the tissue with an associated host 
reaction). It has been considered that a bacterial content of greater than 
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105//g tissue comprises clinical infection and may delay healing (Fowler 
1990).  
The indiscriminate use of topical antibiotics for the routine treatment of 
colonised or infected wounds (Drug and Therapeutics Bulletin 1991), can 
provoke delayed hypersensitivity reactions super infections and select 
for resistance (Kaye 2000) which is a serious problem.  
1.3.2. Absesses 
An abscess is a collection of pus (dead neutrophils) that has 
accumulated in a cavity formed by the tissue as a defensive reaction to 
prevent the spread of infectious materials caused by organisms (e.g. 
bacteria or parasites) or other foreign materials (e.g. splinters or bullet 
wounds) to other parts of the body through the abscess wall, or capsule, 
that is formed by the adjacent healthy cells. However, such 
encapsulation tends to prevent immune cells from attacking bacteria in 
the pus, or from reaching the causative organism or foreign object. 
Therefore, abscesses rarely heal themselves, they require a prompt 
medical attention at the first suspicion of an abscess, and especially that 
it could be fatal when it compresses vital structures such as the trachea. 
Abscesses do not generally need to be treated with antibiotics, but they 
will require surgical intervention, debridement and curettage (Leaper 
2007). After draining (e.g. lancing) abscesse, painkillers and possibly 
antibiotics may be required (Green et al. 2000). Antibiotic therapy alone 
without surgical drainage of the abscess is seldom effective due to 
antibiotics often being unable to get into the abscess and their 
ineffectiveness at low pH levels.  
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As Staphylococcus aureus is a common cause, an anti-staphylococcus 
antibiotic such as flucloxacillin or dicloxacillin is used. With the 
emergence of community-acquired methicillin-resistant Staphylococcus 
aureus MRSA, these traditional antibiotics may be ineffective; alternative 
antibiotics effective against community-acquired MRSA often include 
clindamycin, trimethoprim-sulfamethoxazole, and doxycycline.  
Recurrent abscesses are often caused by community-acquired MRSA, 
which is resistant to most beta lactam antibiotics, but unlike hospital-
acquired MRSA that may only be sensitive to vancomycin IV, they may be 
sensitive to alternative antibiotics, e.g., clindamycin (Cleocin), 
trimethoprim-sulfamethoxazole (Bactrim), and doxycycline (Abraham et 
al. 1997). 
However, recently, efforts to find antibacterial agents from medicinal 
plants are gathering pace. Indeed, this study is part of such efforts, 
where, the antibacterial properties of twelve medicinal plants have been 
investigated. 
1.4. Methods of Medicinal Plants 
Investigation 
To study medicinal plants, various methods have been reported:  
1. Phytochemical approach that searches for classes of secondary 
metabolites containing various antimicrobial substances such as 
alkaloids, isothiocyanates, etc. This approach is considered easy to 
perform, hence its popularity. 
2. Collection of all available plant parts, irrespective of prior knowledge 
and experience. This approach is considered expensive and 
laborious. 
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3. Selection of plants based on published reports on their antimicrobial 
activities.  
4. Ethnomedical approach, where selection of plants and focused 
evaluation is based on oral or written information on the medicinal 
use of a plant, which can be obtained from organised traditional 
medical systems (Ayurveda, Unani, Kampo, shamanism and 
traditional Chinese medicine), herbalism and folklore.  
5. Non-systematic ethnomedical approach (serendipity), where plant 
selection is based on ethnomedical use, but where the revealed 
bioactivity is unexpected and depends on chance (Fabricant and 
Farnsworth, 2001). 
Ethno-directed method, which is widely used by researchers, was 
chosen in this study for the fundamental role it would play in biodiversity 
prospecting in general (Cordell 2000) and in this part of the world in 
particular. The main objectives were to add-on to the inventory of the 
medicinal species that are traditionally used in the Sudan, and evaluate 
the twelve plant species’ antibacterial activities. 
1.5. Study objectives 
1.5.1. General Objectives: 
Extraction and test of twelve medicinal plants, and characterisation of 
their bioactivity, to add-on to the inventory of the medicinal plant 
species that are used traditionally in treating infectious diseases. 
1.5.2. Specific Objectives: 
 
1. Carrying primary screening assays using standard 
bacterial agents to a selection of extracts with promising 
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pharmacological action, the so-called “hits”, that are 
worthy of following-up. 
2. Isolation of bacterial organisms prevalent in wounds and 
abscesses, and determination of their susceptibility to the 
extracts of the test medicinal plants, adopting specialised 
in vitro bioassays to define “lead” status. 
1.6. Test Medicinal Plants 
1.6.1. Piper cubeba L. 
1.6.1.1. Habitat, Origin and Botanical Description  
Piper cubeba L. is of the Order Piperales and the Family Piperaceae. It is 
known in English as Jawa Peppercorn and Jawanese Pepper, and known 
in Arabic as “Kabaaba” (ﺔَﺑﺎَﺒَآ) and "Habb-ul-Uruus" ( ﺐﺣ سوﺮﻌﻟا ). It inhabits 
the Isles of the Indian Ocean and is cultivated in various parts of the 
world. The berries of Piper cubeba L. are commonly known as cubeb and 
are important as a source of pepper (the dried berries) for the worldwide 
spice market (Usia et al., 2005 b). The fruit is pungent and bitter with a 
strong terpene aroma.  
1.6.1.2. Major Chemical Constituents 
Phytochemical and biological investigations have shown three groups of 
secondary metabolites from the berries of Piper cubeba L., i.e. alkaloids, 
lignans composed of cubebin and several related compounds: hinokinin, 
clusin, dihydroclusin, dihydrocubebin and more, and terpenoids 
(essential oil) composed of monoterpenes (sabinene 50%, carene, α-
thujene, 1,4-cineol and 1,8-cineol) and sesquiterpenes (copaene, α- and 
β-cubebene, δ-cadinene, caryophyllene, germacrene, cubebol). The 
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lignans and the essential oil have been more intensively investigated, 
since Piper cubeba L. accumulates both groups of compounds in 
relatively high amounts. On the other hand, reports showed that, 
piperine is an abundant alkaloid in the berries of this species (Parmar et 
al., 1997).  
1.6.1.3. Medicinal and Pharmacological Activities 
a. Antibacterial activity 
The crude ethanol extract from Piper cubeba L. seeds, cubebin and its 
semi-synthetic derivatives, (-)-hinokinin were found to be effective 
against oral pathogens, namely against Streptococcus salivarius, 
Streptococcus mitis and Enterococcus faecalis (Silva et al. 2007). 
b. Other Activities 
Piper cubeba L. is used in traditional medicine to treat gonorrhea, 
dysentery, syphilis, abdominal pain, diarrhea, enteritis and asthma (, 
2001).  
Recent studies have shown that Methanol and water extracts of Piper 
cubeba L. berries posses an inhibitory effect against the hepatitis C virus 
(Hussein et al., 2000), and anti-inflammatory, antioxidant, antiallergic 
and analgesic activities (Choi and Hwang, 2003, 2005).  
Lignans are an important group of secondary metabolites of Piper 
cubeba L.  in terms of their biological activity. More than twenty lignans 
have been reported (Parmar et al., 1997; Usia et al., 2005a), to have 
biological activities. Some were found to be effective against enzymes 
such as cytochrome P450 that were responsible for metabolism of 
currently used drugs (Usia et al., 2005 a,b). Other Lignans were found to 
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have antifeedant, anti-inflammatory, analgesic and trypanocidal 
properties.  
Yatein, hinokinin, cubebin, dihydrocubebin were found to have 
antifeedant activity against a number of stored product insects 
(Harmatha and Nawrot, 2002). Cubebin has been shown to posses anti-
inflammatory, analgesic and trypanocidal activities (Borsato et al., 2000; 
Bastos et al., 2001; De Souza et al., 2005).  
Some of the above mentioned lignans could be used as biosynthetic 
precursors. Hinokinin because of its structural relationship, it can be 
synthesised using cubebin as precursor (Da Silva et al., 2005). Yatein 
could be used as a biosynthetic precursor of deoxypodophyllotoxin and 
podophyllotoxin that are well known for their anticancer properties. 
1.6.2. Acorus calamus L.  
1.6.2.1. Habitat, Origin and Botanical Description 
Acorus calamus L. of the order (Arales) and the family Araceae, known in 
English as Sweet Flag, Myrtle Flag and Sweet Sedge, and known in 
Arabic as “Athareera” (ﻩﺮﻳرﺬﻟا). It is a semi-aquatic plant growing in damp, 
marshy places throughout the world. It is a perennial, aromatic herb with 
creeping rhizomes. The leaves are long, slender, sword-shaped and 
simple, arising alternately from the horizontal rhizomes. These are 
longitudinally fissured with nodes, somewhat vertically compressed and 
spongy internally. Flowers small, fragrant, pale green in a spadix; fruits 
are a three-celled fleshy capsule. 
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1.6.2.2. Major Chemical Constituents 
Known phytoconstituents of Acorus calamus L. parts used: include 
glucoside acorin, alkaloid, Emetic, 1.5–3.5% essential oil and methyl 
isoeugenol (Harborne and Baxter, 1995) 
Essential oils found in Acorus calamus L. include β-Asarone (isoasarone) 
which is usually the major constituent but is present in highly variable 
proportions and occasionally absent (Sinha 2001); a-Asarone, elemicine,  
cis-isoelemicine, cis and trans isoeugenol and their methyl ethers; 
camphene; P-cymene; β –gurjunene; a-selinene; β –cadinene; camphor; 
terpinen-4-01; a-terpineol and a-calacorene; acorone; acorenone; 
acoragermacrone; 2-deca-4,7-dieno1; shyobunones; isoshyobunones; 
calamusenone; linalool and pre-isocalamendiol are also present. 
Other chemicals found in Acorus calamus L. include acoradin, galangin,  
2,4,5-trimethoxy benzaldehyde, 2,5-dimethoxybenzoquinone, 
calamendiol, spathulenol and sitosterol. 
1.6.2.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
Growth of cultured Gram-positive and Gram-negative organisms was 
found to be inhibited significantly by an extract of the Acorus calamus L. 
rhizome. Also, consistent and gradual decrease in replication of 
standard cultures of Staphylococcus aureus , Escherichia coli and 
Shigella flexneri was observed after treatment with Acorus calamus L 
essential oil (Singh .al. et, 2001, Mc Gaw et. al., 2002, Parekh, and 
Chanda 2007).  
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b. Other Activities 
Acorus calamus L. has long been known for its medicinal value. It 
originated in Europe but has been extensively used in Ayurveda, 
particularly to enhance memory. Its powder mixed with ghee (coocked 
clear cream) is given ritually in India to newborn babies on the seventh 
day to improve the intellect and speech development. In China it is used 
in a similar way, to improve speech and aid recovery from stroke. The 
powder of Acorus calamus L is sometimes blown into the nose of a 
patient in a coma to help regain consciousness. There are several 
polyploid varieties to be found, some of which do not contain the toxic 
constituent β-asarone, and these are preferable for medicinal use. 
Acorus calamus L. rhizomes are used in many different disorders, mainly 
as a nerve stimulant, to enhance memory and as an aromatic digestive. It 
is considered to be the remogenic, rejuvenative and sedative. Other uses 
for the plant include diuretic, expectorant, decongestant, anti-
inflammatory, aphrodisiac, anticonvulsant and antibacterial. It has also 
been used in the treatment of epilepsy, chronic diarrhoea, dysentery, 
bronchial catarrh, intermittent fever and certain tumours (Zanoli et. 
al.1998). The main activities of Acorus calamus L. are summarised as:  
1. Antiulcer and cytoprotective activity: The ethanolic extract of the 
rhizome has shown to protect the gastroduodenal mucosa against 
injuries caused by indomethacin, reserpine and cysteamine, and also 
in a pyloric ligation model.  
2. Antispasmodic activity: Experiments on the ileum, uterus, bronchial 
muscles, tracheal chain and blood vasculature showed the relaxant 
and antispasmodic activity of β -asarone and the essential oil of the 
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rhizome. The rhizome is useful in the treatment of diarrhoea and 
dysentery, combined with ginger for relief in flatulent colic. 
3. Analgesic activity: The essential oil and alcoholic extract of the 
rhizome were shown to possess analgesic properties and also mild 
hypotensive and sedative action.  
4. Anti-inflammatory activity: An extract of the rhizome was studied in 
acute, chronic and immunological models of inflammation, including 
carrageenan-induced rat paw oedema, and compared with the 
activity of hydrocortisone. The extract showed significant 
antiinflammatory activity with a reduction of up to 44%. The essential 
oil is also an effective antiinflammatory agent and a coconut oil 
extract of the rhizome produced a 45% inhibition of carrageenan-
induced rat paw oedema and 61 % inhibition using the granuloma 
pouch method. 
5. Anticonvulsant activity: A polyherbal compound containing rhizome of 
Acorus calamus L. as one of the ingredients has been reported 
clinically to reduce epileptic attacks in patients by up to 50%. 
Treatment continued for 6 months resulted in cure in 66 out of 88 
patients and no repeat episodes were reported after 2 years of the 
treatment. The isolated constituents of the rhizomes, asarone and β-
asarone, showed anticonvulsant activity in experimental models. 
There was a decrease in sociability scores with a reduction in 
anticholinergic action. Experiment on animal models also revealed 
the depressant action of the essential oils and the crude alcoholic and 
aqueous extracts of the rhizomes. 
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1.6.3. Anogeissus leiocarpus  
1.6.3.1. Habitat, Origin and Botanical Description  
Anogeissus leiocarpus is of the order Myrtales and the family 
Combretaceae. It is known in English as Axlewood tree and in Arabic as 
“Al-Sahab” (ﺐﺤﺼﻟا), it is a graceful tree of the Sahel to forest zones, 
straight tapering boles up to 20 m high, with greyish white and scaly 
bark, it branches from low down often gregarious and effectively 
weeding out competing grasses (Dalziel, 1937). Its leaves are alternate; 
ovate-lanceolate; apex acute; base-auenuate; pubescent beneath. 
Inflorescences are globose heads, yellow and petals are absent. Fruits 
are globose, cone-like heads, broadly winged, coriaceous, and dark 
grey. 
1.6.3.2. Major Chemical Constituents 
The Anogeissus leiocarpus parts were generally found to contain 
important bioactive substances such as glycosides, phenols, tannins, 
saponins, alkaloids, steroids, ellagic acids and anthraquinones. These 
agents may be responsible for the antibacterial activity of this plant 
(Mann et. al. 2008).  
1.6.3.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
The extract of Anogeissus leiocarpus demonstrated appreciable activity 
against aerobic Staphylococci and Streptococci, and against the 
facultative Gram negative rods (Escherichia, Citrobacter, and 
Enteroabacter spp.). Although, gram-negative organisms tend to have a 
higher intrinsic resistance to most antimicrobial agents, Anogeissus 
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leiocarpus is impressively active against the Gram-negative organisms 
(Taiwo et. al.1999, Ndukwo et. al. 2005). This confirms that Anogeissus 
leiocarpus and many other plants used in Africa and elsewhere as 
chewing sticks can be regarded as candidates for extraction of 
substances, which may be used as antibacterial agents for treatment of 
oral infections caused by a broad spectrum of pathogenic organisms. 
However, comprehensive toxicological investigations must be carried 
out beforehand as toxicity of Anogeissus leiocarpus to mice has been 
reported (Rotimi et. al. 1988).  
In vitro investigations showed that the extracts of combination of the 
three parts of Anogeissus leiocarpus have antibacterial activity against 
clinical isolates of Staphylococcus aureus, Escherichia coli and 
Pseudomonas aeruginosa. The highest antibacterial activity was 
observed against Staphylococcus aureus (Mann et. al. 2008). 
a. Other Activities 
Anogeissus leiocarpus leaves are used as fodder for livestock. It is also 
used in traditional medicine as a remedy for many ailments of both 
livestock and man, which include helminthosis, schistosomiasis, leprosy, 
diarrhoea and psoriasis (Onyeyili, 2000). Roots are commonly used as 
chewing sticks in oral hygiene in Africa including the Sudan and other 
parts of the world; and the decoction of the barks are used against 
cough.  
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1.6.4. Calendula arvensis  
1.6.4.1. Habitat, Origin and Botanical Description  
Calendula arvensis is of the order Compositae and the family Asterales. 
There are two known species, Calendula officinalis and Calendula 
arvensis, and known in English as Field marigold, Garden marigold, 
Goldbloom, Holligold, Maravilla and Marybud; and in Arabic is known as 
“Alhanwa” (ﻩﻮﻨﺤﻟا). It is an annual herbaceous self-seeding plant bright 
yellow or gold flowers that bloom from May until October; it grows to 
about two feet tall with multiple branches. Its flowers follow the sun; 
hence, it was linked to the astrological sign of summer, Leo. Calendula 
arvensis is native to central Europe and the Mediterranean; it grows 
readily in sunny locations throughout North America Europe. It also, 
grows in Asia and Africa including the Sudan, and it was cultivated by the 
Egyptians, Greeks, Hindus and Arabs, and has been used in traditional 
medicine since the 12th century.  
1.6.4.2. Major Chemical Constituents  
Six different saponin glycosides are identified in Calendula arvensis  
(Vidal-Ollivier and Balansard, 1989). These compounds are derivatives of 
oleanolic acid and are known as glycosides A-D, D2, and F. Several 
glucuronides are also identified in these species (Szakiel et. al, 1990). 
The content of oleanolic acid and its glycoside and glucuronide 
derivatives are found in the flowers and leaves (Vidal-Ollivier and 
Balansard, 1989). The flowers also contain carotenoids, mainly 
citroxanthine, flavochrome, beta-carotene, and flavoxanthine, that 
produce a golden yellow color (Anon, 1998), as well as isorhamnetin and 
quercetin (Bezakova et al.1996). Three different faradiol esters were 
also found in the flowers (Zitterl-Eglseer et al. 1997). In Calendula 
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arvensis, sesquiterpene glycosides (De Tommasi N and Pizza 1990, 
Ahmed et al. 1993) and triterpenoid saponins (De Tommasi 1991) were 
isolated from the aerial parts of the plant. Among the sesquiterpene 
glycosides are the epicubebol and alloaromadentol compounds, which 
contain a cyclopropane ring structure (De Tommasi N and Pizza 1990, 
Ahmed et a., 1993). Oil that contains volatile components along with 
carotenoids can also be extracted from the blossoms and the small dry 
fruits (Baranyk 1995) of Calendula arvensis.   
1.6.4.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
Calendula arvensis as antibacterial, in vitro studies gave conflicting 
results. Some studies showed antibacterial effects against Bacillus 
subtilits, Escherichia coli, and Staphylococcus aureus (Janssen et al, 
1986); the arvensosides B and D were somewhat active against 
Trypanosoma brucei (Dvorzak 1989). In other studies, Calendula 
arvensis was inactive against Aerobacter aerogenes, Bacillus subtilis, 
Escherichia coli, Klebsiella pneumonia, Proteus morganii, Proteus 
vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Strep faecalis, 
Staphylococcus aureus (Acevedo et al. 1993).  
b. Other Activities 
Calendula arvensis is used in traditional medicine (Vidal-Ollivier and 
Balansard 1989) as an anti-inflammatory agent against sunburn, for 
example, and as an antipyretic (Vidal-Ollivier and Balansard 1989, De 
Tommasi et al., 1990). It is taken internally to assist and promote 
menstrual discharge in women, in promoting wound healing (Vidal-
Ollivier and Balansard, 1989, Anon, 1998, Kathi 1999), and in cancer 
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treatment (De Tommasi et al., 1990, Kathi and Kember 1999).  Calendula 
arvensis is known to accelerate the formation of new tissue, therefore 
the flowers were made into extracts, tinctures, balms and salves and 
applied directly to the skin to treat various skin conditions, such as dry 
skin in babies, eczemas, and cuts (Anon, 1998, Kathi and Kember 1999).  
In Italian folk medicine Calendula arvensis is used as an antipyretic and 
anti-inflammatory. Teas made from it are used as eye washes, gargles or 
compresses to treat conjunctivitis, pharyngitis, aphthous stomatitis and 
gingivostomatitis, diaper rashes and other inflammatory conditions of 
the skin and mucus membranes (Fleming 1998). In India, herbal 
compounds including Calendula arvensis are used topically to treat 
hemorrhoids. Calendula arvensis cream alone or in combination with 
other remedies is also a favorite homeopathic remedy to treat abrasions 
and minor burns. Dried Calendula arvensis petals are used in the spice 
trade as an inexpensive alternative to saffron and are used in many 
ointments to enhance their appearance by adding a gold colour. Like 
other members of the daisy family, the dried flowers have also been used 
as an insect repellent. Some herbalists combine Calendula arvensis, 
comfrey, and echinacea and St. John’s wort in a cream or ointment as an 
all-purpose skin salve (Kember 1999). 
Calendula arvensis has Gastrointestinal/hepatic activity, namely against 
Chronic colitis and ulcers (Chakurski et al 1981). Also, it has 
reproductive activity, it has estrogenic and uterotonic effects. In vitro 
studies showed that its extracts exhibited moderate uterotonic effects in 
isolated rabbit and guinea pig uterine horn tissues (Shipochliev 1981). 
Calendula arvensis has immune modulation activity; it is a 
immunostimulant and anti-inflammatory. As an Immunostimulant, in vitro 
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studies showed that its polysaccharides might stimulate phagocytosis 
(Wagner et al, 1985). As an anti-inflammatory, in vitro studies showed 
that Calendula arvensis’ glycosides inhibited lipoxygenase activity 
(Bezakova et al. 1996). In several studies, Calendula arvensis’ 
triterpenoids (especially the faradiol monoester) reduced experimentally 
induced inflammation in mice (Yasukawa et al. 1993, Loggia et al. 1994, 
Akihisa et al. 1996, Zitterl-Eglseer et al. 1997). Rats with long-standing 
ocular inflammation improved when treated with Calendula arvensis 
eyewashes; however, there was no comparison group in this study. 
Anecdotal cases report decreased pain and inflammation in 
postmastectomy patients (Smith 1983) and in children with chronic 
suppurative otitis media.No controlled trials have been reported.  
Calendula arvensis has antimicrobial (antiviral, antibacterial, antifungal) 
activity. As antiviral, studies gave conflicting results. Its sesquiterpene 
glycosides inhibited replication of rhinovirus and Herpes virus (De 
Tommasi et al, 1990, 1991); Calendula arvensis extracts also displayed 
some anti-HIV activity, including a dose-response effect against reverse 
transcriptase activity (Kalvatchev 1997); another study demonstrated 
activity against Herpes simplex and influenza viruses. However, other 
studies showed no antiviral activity against polio, vaccinia, influenza or 
Herpes viruses. 
1.6.5.  Nauclea latifolia  
1.6.5.1. Habitat, Origin and Botanical Description  
Nauclea latifolia is of the order Rubiales and the Rubiaceae family, 
known in English as Pin cushion tree, and in Arabic as the “Karmadoda” 
(ةدوﺪﻣﺮآ). It is glabrous shrub or small tree with drooping branches. 
Leaves are opposite, elliptic-oblong, apex acuminate, base cuneate to 
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subcordate, margin entire and Inflorescences terminal globose heads. 
Its fruits drupes, globose with granulated surface. Nauclea latifolia is a 
widely distributed savanna plant. It is found in the forest and fringe 
tropical forest.  
1.6.5.2. Major Chemical Constituents 
Key constituents of Nauclea latifolia are indole-quinolizidine alkaloids 
and glycoalkaloids, tannins and sapponins (Iwu 1993, Iwu et al 1999, El-
Mahmood et al. 2008).  
1.6.5.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
Studies showed that Nauclea latifolia has antibacterial activity against 
gram positive and negative bacteria and antifungal activity (Iwu 1993, 
Iwu et al 1999). It is most effective against Corynebacterium diphtheriae, 
Staphylococcus aureus Streptobacillis sp., Streptococcus sp., Neisseria 
sp., Pseudomonas aeruginosa, Salmonella spp and Escherichia coli 
(Deeni 1991).  Escherichia coli, though a Gram-negative bacterium, has 
been reported to be sensitive to extracts of Nauclea latifolia (Omer et al., 
1998, Abreu et al., 1999, Umeh et al 2005).  
b. Other Activities 
Medicinal uses of Nauclea latifolia are tonic and fever medicine, chewing 
stick, toothaches, dental caries, septic mouth and malaria, diarrhea and 
dysentery.The maceration of the barks is used to irradicate tape worms 
(Lamidi 1995, Iwu et al 1999). 
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1.6.6. Petasites hybridus  
1.6.6.1. Habitat, Botanical Description Origin and 
Uses 
Petasites hybridus of the Order Asterales and the Family Asteraceae. It 
is known in Enlglish as Butterbur which is attributed to the large leaves 
being used to wrap butter during warm weather (Butterbur 1971). Other 
names include Bog rhubarb, Devil's hat and Pestilence. In Arabic it is 
known as “Fikhet” (ﺖﻬﻜﻓ). It is herbaceous perennial plant usually found 
in wet, marshy ground, in damp forests, and adjacent to rivers or 
streams. It is native to Europe and Northern Asia, but found throughout 
Europe as well as parts of Asia and North America. The flowers are 
produced in the early spring, before the leaves appear; flowering shoots 
up to 40 cm tall and the flowers are pale pink, with several 
inflorescences clustered on a 5-20 cm stem. The leaves are large, on 
stout 80-120 cm tall stems, round, with a diameter of 40-70 cm (USDA, 
NRCS 2006, Monograph, 2001).  
1.6.6.2. Major Chemical Constituents 
The main active constituents that are isloted from the Petasites hybridus 
rhizomes, roots, and leaves are two sesquiterpenes, petasin and 
isopetasin. Petasin is responsible for the antispasmodic properties of the 
plant by reducing spasms in smooth muscle and vascular walls, in 
addition to providing an anti-inflammatory effect by inhibiting leukotriene 
synthesis. Prostaglandins are important mediators in the inflammatory 
process and isopetasin's positive impact on prostaglandin metabolism 
contributes to the effectiveness of Petasites hybridus extracts. Extracts 
of the plant also contain volatile oils, flavonoids, tannins, and 
pyrrolizidine alkaloids. As these alkaloids are believed to be toxic to the 
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liver and carcinogenic in animals, extracts in which contain the 
pyrrolizidine alkaloids must be removed (Seeram et al. 2005). 
1.6.6.3. Medicinal and Pharmacological Activities 
Extract from Petasites hybridus with three main compounds oxopetasan 
esters, petasin and isopetasin were found to inhibit the biosyntesis of the 
vasoconstrictive peptide leukotrienes, hence contributing to 
gastroprotection and spasmolyticactivity (Bickel et al. 1994).  
Traditional medical uses of Petasites hybridus include its applications as 
a diuretic and muscle relaxant, and in treating coughs, fever, wounds, 
stammering, headaches, asthma and stress (USDA, NRCS 2006, 
Monograph, 2001). Currently, its main uses include prophylactic 
treatment of migraines, and as an antispasmodic agent for chronic 
cough or asthma. It has also been used successfully in preventing 
gastric ulcers, and in treating patients with irritable bladder and urinary 
tract spasms (Mauskop 2000). 
1.6.7. Salvia officinalis  
1.6.7.1. Habitat, Origin and Botanical Description  
Salvia officinalis is of the order Lamiales and the Labiatae family, it is 
known in English as the Garden sage, Kitchen sage, and Dalmatian sage, 
and in Arabic is known as “Mariamia” (ﺔﻴﻤﻳﺮﻣ). It is a small evergreen 
subshrub, with woody stems, grayish leaves, and blue to purplish 
flowers. It is in leaf all year, in flower from June to August, and the seeds 
ripen from August to September. The flowers are hermaphrodite. It is 
native to the Mediterranean region. It grows on dry banks and stony 
places (Polunin 1969), usually in limestone areas and often where there 
is a very little soil (Grieve 1984).  
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Salvia officinalis is much cultivated as a kitchen and medicinal herb. 
Common sage is also grown in parts of Europe, especially the Balkans 
for distillation of the essential oil. 
1.6.7.2. Major Chemical Constituents 
Salvia officinalis contains essential oils including cineole, borneol, 
thujone, α-thujene, α-pinene, camphene, 2-β-pinene, β-myrcene, α-
terpinene,1,8-cineole, γ-terpinene, α-thujone, β-thujone, camphor. 1-
borneol, 1,4 terpineol, endobornyl acetate, caryophyllene, β-selinene, 
veridiflorol and manool (Miladinović and Miladinović 2000). Its leaf 
contains tannic acid, oleic acid, ursonic acid, ursolic acid, cornsole, 
cornsolic acid, fumaric acid, chlorogenic acid, caffeic acid, niacin, 
nicotinamide, flavones, flavone glycosides, and estrogenic substances. 
1.6.7.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
The crude extracts of Salvia officinalis  posses (Velickovic et al 2003) 
antibacterial activities towards the Gram-positive bacteria ( Bacillus  
subtilis and MRSA) but no activity was shown against the Gram-negative 
bacteria (enterohemorrhagic Escherichia coli and Pseudomonas 
aeruginosa) which was attributed to the permeability barrier provided by 
the cell wall or to the membrane accumulation mechanism (Adwan 1998, 
Abu-Shanab 2004 ). 
In another study the essential oil from leaves of Salvia officinalis showed 
antibacterial activity against Bacillus subtilis, Staphylococcus aureus , 
Escerichia coli and Salmonella  enteritidis  (Velickovic et al 2003) , as 
well as Klebsiella pneumuniae, Proteus mirabilis, Morganella morganii, 
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Enterobacter aerogenes, Klebsiella oxytoca  and Pseudomonas 
aeruginosa (Miladinović and Miladinović,2000).  
b. Other Activities  
Salvia officinalis has been recommended at one time or another for 
virtually every ailment. Modern evidence supports its effects as an 
antihydrotic, antibiotic, antifungal, astringent, antispasmodic, 
estrogenic, hypoglycemic, and tonic. In a double blind, randomized and 
placebo-controlled trial, sage was found to be effective in the 
management of mild to moderate Alzheimer's disease (Akhondzadeh et 
al. 2003).  
Salvia officinalis  used internally for indigestion, gas, liver complaints, 
excessive lactation, excessive perspiration, excessive salivation, 
anxiety, depression, female sterility, menopausal problems; and 
externally for insect bites, throat, mouth, gum, skin infections, vaginal 
discharge. 
The crude extracts of Salvia officinalis showed antifugal activity against 
Aspergillus niger (Velickovic et al 2003). The leaves of Salvia officinalis 
L. are reported to have a wide range of biological activities, such as anti-
bacterial, fungistatic, virustatic, astringent, eupeptic and anti-hydrotic 
effects. Also it was found to potentiate memory retention and it has an 
interaction with muscarinic and nicotinic cholinergic systems that is 
involved in the memory retention process (Eidi et al).  
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1.6.8. Punica granatum L. 
1.6.8.1. Habitat, Origin and Botanical Description  
Punica granatum L. is of the order Myrtales and the Punicaceae family, it 
is known in English as Pomegranate, and in Arabic as “Alroman” (نﺎﻣﺮﻟا). 
It is a neat, rounded shrub or small tree that can grow to 20 or 30 ft., but 
more typically to 12 to 16 ft. in height. Dwarf varieties are also known. It 
is usually deciduous, but in certain areas the leaves will persist on the 
tree.  
Punica granatum L. leaves are glossy leathery and narrow and lance-
shaped. The trunk is covered by a red-brown bark which later becomes 
grey. The branches are stiff, angular and often spiny, and they have the 
tendency to sucker from the base. The flowers are attractive scarlet, 
white or variegated and are over an inch across and have 5 to 8 
crumpled petals and a red, fleshy, tubular calyx which persists on the 
fruit. The flowers may be solitary or grouped in twos and threes at the 
ends of the branches. Punica granatum L is self-pollinated as well as 
cross-pollinated by insects. The fruit is nearly round, 2-1/2 to 5 in. wide 
fruit is crowned at the base by the prominent calyx. The tough, leathery 
skin or rind is typically yellow overlaid with light or deep pink or rich red. 
The interior is separated by membranous walls and white, spongy, bitter 
tissue into compartments packed with sacs filled with sweetly acid, juicy, 
red, pink or whitish pulp or aril. High temperatures are essential during 
the fruiting period to get the best flavour (Morton 1987; Stephen 1990).  
Punica granatum L. prefer a semi-arid mild-temperate to subtropical 
climate and are naturally adapted to regions with cool winters and hot 
summers. A humid climate adversely affects the formation of fruit. The 
tree can be severely injured by temperatures below 12° F. It is native of 
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the area spaning from Iran to the Himalayas in northern India and was 
cultivated and naturalised over the whole Mediterranean region since 
ancient times. It is widely cultivated throughout India and the drier parts 
of Southeast Asia, Malaya, the East Indies, tropical Africa and America 
(Butterfield 1963). 
1.6.8.2. Major Chemical Constituents 
Punica granatum L. major class of phytochemical includes the 
polyphenols, flavonoids, condensed tannins and hydrolysable tannins. 
Hydrolysable tannins are predominant polyphenols found in 
pomegranate juice and account for 92% of its antioxidant activity (Gil  et 
al. 2000). When crushed and dried, the seeds produce oil with 80% 
punicic acid, the 18-carbon fatty acid, along with the isoflavone 
genistein, the phytoestrogen coumestrol, and the sex steroid estrone. 
The seed coat of the fruit contains delphinidin-3-glucoside,  
delphinidin-3,5-diglucoside, cyanidin-3-glucoside, cyanidin-3,5-
diglucoside, pelargonidin-3-glucoside, and pelargonidin-3,5-diglucoside 
with delphinidin-3,5-diglucoside being the major anthocyanin in Punica 
granatum L juice (Afaq et al. 2004 ). Punica granatum L extract has also 
been shown to protect from NSAID and ethanol-induced gastric 
ulceration (Ajaikumar et al. 2005). 
1.6.8.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
Punica granatum L. juice has shown to inhibit serum angiotensin-
converting enzyme, and hence reducing systolic blood pressure (Aviram 
and Dornfeld 2001). Also, it has shown to inhibit viral infections (Neurath 
et al. 2004), and may have antibacterial effects against dental plaque 
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(Menezes et al. 2006). In the Midle East, Punica granatum L. are used to 
cure mouth ulcers, where the syrup is sieved boiled to form molasses 
and then applied directly to the mouth ulcer.  
b. Other Activities 
Punica granatum L. is used in traditional medicine for the treatment and 
prevention of arthritis and other inflammatory diseases. Rececent 
studies showed that standardised extracts of Punica granatum L. fruit 
possess anti-inflammatory and cartilage sparing effects (Ahmed et al. 
2005), inhibits the proliferation of human cancer (Seeram et al. 2005; 
Afaq et al. 2004; Aviramet al. 2000; Syed et al. 2006; Adams et al. 2006) 
and it reduces the growth of prostate tumors and the levels of prostate-
specific antigen (Malik 2005). Also, it was reported that consumption of 
Punica granatum L. may have cholesterol lowering and cardiovascular 
and other chronic diseases preventing effects (Esmaillzadeh et al.2006; 
Rosenblat , et al. 2006; de Nigris et al. 2007; Afaq  et al. 2005).  
1.6.9. Cissus petiolata  
1.6.9.1. Habitat, Origin and Botanical Description  
Cissus petiolata of the order Vitales and the Vitaceae family, it is known 
in English as (Bitter apple and Bitter gourd), and in Arabic as “Irg-
alhagar” ( قﺮﻋ ﺮﺠﺤﻟا ). Cissus petiolata grows in fringing forest and 
spreads worldwide, but mainly in tropical and subtropical regions. In 
Africa, it spreads from Guinea Republic to Ethiopia and southwards 
through the Congo, Uganda and Tanzania and reaching its southern limit 
in Angola and Mozambique. It is a vigorous climber; stems quadrangular, 
glabrous, becoming woody when old and developing longitudinal corky 
wings up to 1·2 cm. broad on the angles; tendrils simple. Leaves are 
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simple, glabrous or with a few hairs on the petioles and lower surface of 
the leaf when young; petiole up to 10·8 cm. long but usually shorter; leaf-
lamina up to 13 × 13 cm. but usually somewhat smaller, circular to 
broadly ovate. Flower-buds are conical, up to 3 mm. long. Calyx 1 mm. 
long, pubescent when young. Petals are glabrous, ovary glabrous; style 
1–2 mm long. Fruit is  8 mm in diameter, glabrous. Seeds are up to 4 per 
fruit, only 1 usually becoming fully developed, smooth, 6 mm long with 
one well-marked crest and 2 subsidiary ones.  
1.6.9.2. Medicinal and Pharmacological Activities 
Cissus petiolata is used as medicine for menstrual cycle; tumours, 
cancers (Bark), and stomach troubles (Root) and root-sap is used for ear 
treatment. It is used traditionally for fungal infections treatment (Omar et 
al 2006). Also, Cissus petiolata extracts were found to have toxic activity 
against cercariae and miracidia of Schistosoma mansoni (Elsheikh et al 
1990) 
1.6.10. Moringa peregrine 
1.6.10.1. Habitat, Origin and Botanical Description  
Moringa peregrine is of the Order Brassicales and the Family 
Moringaceae. It known in English as the wild Drum-stick tree and in 
Arabic is known as “Yusor, Al Yassar, and Al Ban” ( ،ﺮﺴﻴﻟا نﺎﺒﻟا ) “shagarat 
al rauwãq” ( ةﺮﺠﺷ قاواﺮﻟا ). Moringa peregrine occurs naturally in arid or 
semi-arid region, it spreads from the Dead Sea area and along the Red 
Sea coasts to northern Somalia and around the Arabian Peninsula to the 
mouth of the Persian Gulf. It grows on rocky slopes of wadis and gullies, 
up to 850 m altitude, sometimes on nearly bare rock with a strongly 
reduced root system. 
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Moringa peregrine is a shrub or small tree up to 10 m tall, with tuberous 
rootstock; bole up to 40 cm in diameter; bark grey, purple-grey or bright 
brown; crown ovoid; branches terete, slender, young stems grey-white 
or waxy blue-green; twigs brittle. Leaves alternate, in bunches at the 
ends of branches, 15–40 cm long, 2–pinnate, with 2–5 pairs of pinnae; 
leaflets opposite or alternate, obovate, oblanceolate or spatulate, 3–20(–
35) mm × 2–10(–13) mm, base cuneate to rounded, apex rounded or 
notched, grey or waxy green. Flowers bisexual, slightly zygomorphic, 5-
merous, white with purple heart or pink-flushed, sometimes scented; 
pedicel 2–9 mm long, jointed; sepals free, oblong to lanceolate, 7–9 mm × 
1.5–3 mm, acuminate, hairy on both surfaces; petals free, narrowly 
oblong, obovate or spatulate, 8–15 mm × 2–5 mm, hairy inside; stamens 
5, free, 4.5–7 mm long, alternating with 5 staminodes, 4–5 mm long; 
ovary superior, shortly stalked, cylindrical, hairy, 1-celled, style slender. 
Fruit an elongate capsule (10–) 32–39 cm × (1–)1.5–1.7 cm, somewhat 
trigonous, slightly narrowed between the seeds, with a beak, glabrous, 
dehiscent with 3 valves. Seeds are globose to ovoid or trigonous, 10–12 
mm × 10–12 mm, brown. 
Moringa peregrina seeds are used to produce oil, called ‘ben oil’. This oil 
use goes back to the Faeroes time. It is used for cooking, in cosmetics 
and in medicine.  
1.6.10.2. Major Chemical Constituents 
The seed of Moringa peregrina contains about 50% oil. The approximate 
fatty acid composition of the oil is: palmitic acid 9%, stearic acid 4%, 
arachidic acid 2%, behenic acid 2%, oleic acid 71%, linoleic acid 1%, and 
gadoleic acid 2%. The oil contains the sterols campesterol, stigmasterol 
and β-sitosterol and the tocopherols α-, γ-, and δ-tocopherol. The water 
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purifying properties of the seed are caused by a protein which 
coagulates dispersed particles. 
1.6.10.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
Extracts Moringa peregrina was found to be active against Pseudomonas 
aeruginosa, Staphylococcus aureus and Candida albicans (Marwah et al. 
2006). 
b. Other Activities 
The juice from the bark of Moringa peregrina is used as a disinfectant 
and to speed up wound healing (Ruchi et al. 2006). The seeds are also 
used as coagulant to purify water, e.g. in Sudan (Jahn 1986). The oil is 
used to treat abdominal pain. 
1.6.11. Biota orientalis  
1.6.11.1. Habitat, Origin and Botanical Description 
Biota orientalis Endl (Thuja orientalis L.) is a gymnospermic plant of the 
family Cupressaceae, order Coniferales. It is known in English as Easern 
red, and in Arabic as “Althoya” (ﺎﻳﻮﺜﻟا) and “Alafssa” (ﺔﺼﻔﻌﻟا). Based on 
morphological and embryological characteristics Biota orientalis Endl, 
which was known as Thuja orientalis L. has been separated from the 
genus Thuja and named as Biota (Buchholz 1948; Singh, and Oberoi 
1962).  
Biota orientalis Endl is a popular graceful and beautiful widely cultivated 
ornamental plant with high medicinal value. It is an evergreen tree with 
profuse branching reaching a maximum height of 15 m. There is 
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considerable variation in shape of the tree under cultivation. The stem 
divides profusely into vertical main branches near the base. The 
branches are covered with minute scale-like dark green, opposite and 
decussate, closely adpressed leaves having a long groove in the middle 
of their abaxial (lower) surface. The leaves are fused with the stem up to 
one third of their length (Gahalain 2006).  
1.6.11.2. Major Chemical Constituents 
Biota orientalis Endl is one of the 50 fundamental herbs (Duke and 
Ayensu 1985) in Chinese herbalism, Both the leaves and the seeds 
contain an essential oil consisting of borneol, bornyl acetate,   thujone, 
camphor and sesquiterpenes (Nguyen and Doan 1989).  
Biota orientalis oil was found to include 3-carene (57.06%), β-pinene 
(6.90%), limonene (4.28%), cis-thujone (4.16%), cedrol (4.08%),  
α-terpineol (3.43%), α-pinene (3.19%), δ-2-carene (2.25%) and about 
2.18% fenchone (Pandey and Chowdhury 2002). 
1.6.11.3. Medicinal and Pharmacological Activities 
a. Antibacterial Activity 
The lipids of the seeds of Biota orientalis are found to be effective 
against various microorganisms including Bacillus megaterium, Bacillus 
brevis, Pseudomonas aeruginosa, Klebsiella pneumonia, Enterobacter 
aerogenes, Staphylococcus and Micrococcus luteus (Metin et al. 2002). 
b. Other Activities 
The leaves of Biota orientalis used fresh or dry are antibacterial, 
antipyretic, astringent, diuretic, expectorant, refrigerant, stomachic and 
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improve hair growth. They are used internally in the treatment of coughs, 
colds, haemorrhages, excessive menstruation, bronchitis, asthma, skin 
infections, mumps, bacterial dysentery, arthritic pain and premature 
baldness. The immature female cones are very effective in the treatment 
of warts. The seed is an aperient, lenitive and sedative. It is used 
internally in the treatment of palpitations, insomnia, nervous disorders 
and constipation in the elderly (Yeung; Brown 1995).  
1.6.12. Ferula asafoetida  
1.6.12.1. Habitat, Origin and Botanical Description  
Ferula asafoetida L. is of the order Apiales and the family Umbelliferae. It 
is known in English as Asafoetida and the devil's dung and in Arabic as 
“Heltit” (ﺖﻴِﺘْﻠَﺣ). It is native to Iran, Arabia and Sudan. Ferula assafoetida 
is herbaceous and monoecious. It grows to 2 m high with a circular mass 
of leaves. Flowering stems are 2.5–3 m high and 10 cm thick, with a 
number of schizogenous ducts in the cortex containing the resinous 
gum. Stem leaves have wide sheathing petioles. Compound large umbels 
arise from large sheaths. Flowers are pale greenish yellow. Fruits are 
oval, flat, thin, reddish brown and have a milky juice. Roots are thick, 
massive, and pulpy. It yields a resin similar to that of the stems. All parts 
of the plant have the distinctive fetid smell (Ross). 
Ferula asafoetida L. has a pungent garlic smell when raw, but in cooked 
dishes, it delivers a smooth flavour, reminiscent of leeks. 
1.6.12.2. Major Chemical Constituents 
Dried Ferula asafoetida L. consists mostly of a resin (25 to 60% of the 
total mass, 60% of which are esters of ferula acid) and a complex 
carbohydrate part (25 to 30%). The essential oil (10%) contains a wealth 
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of sulfur compounds, mainly (R)-2-butyl-1-propenyl disulphide (50%), 1-
(1-methylthiopropyl) 1-propenyl disulphide and 2-butyl-3-methylthioallyl 
disulphide. Furthermore, di-2-butyl trisulphide, 2-butyl methyl 
trisulphide, di-2-butyl disulphide and even di-2-butyl tetrasulphide have 
been found (Rajanikant et al. 1984). The resin portion is known to contain 
asareninotannols 'A' and 'B', ferulic acid, umbelliferone and four 
unidentified compounds (Singhal 1997). 
1.6.12.3. Medicinal and Pharmacological Activities 
Ferula asafoetida L. is traditionally used to treat flatulence and 
spasmodic contraction of stomach and oesophagus with reverse 
peristalsis. It has been found to affect favourably deep ulcerations, 
caries of bones, especially in the syphilitic organism. It is also prescribed 
for respiratory conditions like asthma, bronchitis and whooping cough. 
The of dried root latex powder of Ferula asafoetida L. has molluscicidal 
activity against the snail Lymnaea acuminate (Kumar and Singh 2005). 
1.7. Panel of Standard Antibiotics 
To ensure proper interpretation of the results, four standard antibiotics 
were used for reference, namely Benzylpenicillin, Erythromycin, 
Gentamicin and Ceftriaxone. These four antibiotics are commercially 
available and widely used against the test bacteria.  
1.7.1. Benzylpenicillin 
Benzylpenicillin, commonly known as penicillin G, is the gold standard 
penicillin. It is typically given by a parenteral route of administration (not 
orally) because it is unstable in the hydrochloric acid of the stomach. 
Because the drug is given parenterally, higher tissue concentrations of 
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penicillin G can be achieved leading to increased antibacterial activity. 
Benzylpenicillin is used to treat Cellulitis, Bacterial endocarditis, 
Gonorrhea, Meningitis, aspiration pneumonia, lung abscess, Community-
acquired pneumonia, Syphilis and Septicemia in children (Russell 2002, 
Katzung).  
1.7.1.1. Mechanism of action 
β-lactam antibiotics work by inhibiting the formation of peptidoglycan 
cross-links in the bacterial cell wall. The β-lactam moiety (functional 
group) of penicillin binds to the enzyme (DD-transpeptidase) that links 
the peptidoglycan molecules in bacteria, which weakens the cell wall of 
the bacterium (in other words, the antibiotic causes cytolysis or death 
due to osmotic pressure). In addition, the build-up of peptidoglycan 
precursors triggers the activation of bacterial cell wall hydrolases and 
autolysins, which further digest the bacteria's existing peptidoglycan 
(Russell 2002, Katzung). 
Gram-positive bacteria are called protoplasts when they lose their cell 
wall. Gram-negative bacteria do not lose their cell wall completely and 
are called spheroplasts after treatment with penicillin. 
Penicillin shows a synergistic effect with aminoglycosides, since the 
inhibition of peptidoglycan synthesis allows aminoglycosides to 
penetrate the bacterial cell wall more easily, allowing its disruption of 
bacterial protein synthesis within the cell. This results in a lowered MBC 
for susceptible organisms. 
1.7.1.2. Clinical use 
Penicillin (sometimes abbreviated PCN or pen) is a group of β-lactam 
antibiotics used in the treatment of bacterial infections caused by 
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susceptible, usually Gram-positive, organisms. “Penicillin” is also the 
informal name of a specific member of the penicillin group Penam 
Skeleton, which has the molecular formula R-C9H11N2O4S, where R is a 
variable side chain (Rossi  2006, James 2007). 
1.7.2. Erythromycin 
Erythromycin is a macrolide antibiotic that is similar to but wider than 
that of penicillin in terms of antimicrobial spectrum. It is often used for 
people who are allergic to penicillins. It has a good coverage of atypical 
organisms associated with respiratory tract infections, including 
mycoplasma and Legionellosis. It is also used to treat chlamydia, 
syphilis, acne, and gonorrhoea (Russell 2002, Katzung).  
1.7.2.1. Mechanism of action 
Erythromycin may possess bacteriocidal activity, particularly at higher 
concentrations (Katzung ). The mechanism is not fully elucidated however. 
By binding to the 50S subunit of the bacterial 70S rRNA complex, protein 
synthesis and subsequently structure/function processes critical for life 
or replication are inhibited (Katzung).  Erythromycin interferes with 
aminoacyl translocation, preventing the transfer of the tRNA bound at 
the A site of the rRNA complex to the P site of the rRNA complex. Without 
this translocation, the A site remains occupied and thus the addition of 
an incoming tRNA and its attached amino acid to the nascent 
polypeptide chain is inhibited. This interferes with the production of 
functionally useful proteins and is therefore the basis of antimicrobial 
action (Russell 2002, Katzung). 
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1.7.2.2. Clinical use 
Erythromycin is used to treat (first-line treatment minor wound and skin 
infection that are likely to be infected with staphylococci or streptococci. 
It is also, used as an antibiotic for prophylaxis of wounds at risk of 
developing infection. It may be appropriate in some circumstances for 
wounds to the feet, extensive intra-oral lacerations, or stellate lesions 
(Russell 2002, Katzung). 
1.7.3.  Gentamicin 
Gentamicin is an aminoglycoside antibiotic, used to treat many types of 
bacterial infections, particularly those caused by Gram-negative 
bacteria, including Pseudomonas, Proteus, Serratia, and Gram-positive 
Staphylococcus. However, it is not used for Neisseria gonorrhoeae, 
Neisseria meningitidis or Legionella pneumophila bacterial infections 
(Russell 2002). 
1.7.3.1. Mechanism of action 
Gentamicin binds to bacterial ribosome and induces misreading of 
mRNA hence inappropriate amino acid insertions (bacteriocidal).  It 
requires IV/IM administration and poor CSF penetration (unless 
inflammed meninges). It is filtered unchanged by kidney hence 
accumulate in renal impairment. Gentamicin is active against aerobic 
gram-negative organisms and staphylococci.   
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1.7.3.2. Clinical Use 
Usually used as part of a combination regimen to treat serious sepsis 
(septicaemia). It is also, used topically to treat eye and ear infections 
(Russell 2002). 
1.7.4. Ceftriaxone 
Ceftriaxone is a third-generation cephalosporin; it has broad spectrum 
activity against Gram positive and Gram negative bacteria. In most 
cases, it is considered to be equivalent to cefotaxime in terms of safety 
and efficacy (Russell 2002). 
1.7.4.1. Mechanism of action 
The syn-configuration of the methoxyimino moiety confers stability to β-
lactamase enzymes produced by many Gram-negative bacteria. Such 
stability to β-lactamases increases the activity of ceftriaxone against 
otherwise resistant Gram-negative bacteria. In place of the easily 
hydrolysed acetyl group of cefotaxime, ceftriaxone has a metabolically-
stable thiotriazinedione moiety (Russell 2002). 
1.7.4.2. Clinical Use 
Ceftriaxone is often used (in combination, but not direct, with macrolide 
and/or aminoglycoside antibiotics) for the treatment of community-
acquired pneumonia. It is also a choice drug for treatment of bacterial 
meningitis. In pediatrics, it is commonly used in febrile infants between 4 
and 8 weeks of age who are admitted to the hospital to exclude sepsis. It 
has also been used in the treatment of Lyme disease and gonorrhoea 
(Russell 2002). 
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1.8. Test Bacterial Organisims  
In this study bacteria prevalent in abscesses and wounds were isolated 
and used to determine their susceptibility to extracts of 12 medicinal 
plants. And for reference, a panel drug-sensitive reference bacterial 
strains that belongs to different classes and consist of Gram-positive and 
Gram-negative bacteria was used. 
The bacteria species used were Escherichia coli, Klebsiella spp and 
Proteus vulgaris of the Enterobacteriaceae group, Staphylococcus 
aureus of the Staphylococci group, Pseudomonas aeruginosa of the 
Pseudomonads group, and Bacillus subtilis of the Bacilli group. 
Characteristics, Classification and diseases caused by bacteria of these 
groups are reviewed below: 
1.8.1.  Enterobacteriaceae 
The Enterobacteriaceae are a large, heterogeneous group of gram-
negative rods whose natural habitat is the intestinal tract of humans and 
animals. The family includes many genera (eg, Escherichia, Shigella, Sal-
monella, Enterobacter, Klebsiella, Serratia, Proteus,) and others. Some 
enteric organisms, eg, Escherichia coli, are part of the normal flora and 
incidentally cause disease, while others, the salmonellae and shigellae, 
are regularly pathogenic for humans. The Enterobacteriaceae are 
facultative anaerobes or aerobes, ferment a wide range of 
carbohydrates, possess a complex antigenic structure, and produce a 
variety of toxins and other virulence factors. Enterobacteriaceae, enteric 
gram-negative rods, and enteric bacteria are the terms used generally, 
but these bacteria may also be called coliforms (Blair et al 1970, Jawetz, 
et al 1995). 
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1.8.1.1. Classification  
The taxonomy of the Enterobacteriaceae is complex and is rapidly 
changing as further DNA homology studies are performed. More than 20 
genera and 100 species have been defined (Kelly and Farmer 1991).  
The family Enterobacteriaceae is characterised biochemically by the 
ability to reduce nitrates to nitrites and to ferment glucose with the 
production of acid or acid and gas. The Enterobacteriaceae do not 
require increased amounts of sodium chloride for growth and are 
oxidase-negative. Many biochemical tests are used to differentiate 
species of Enterobacteriaceae (Blair et al 1970, Jawetz, et al 1995).  
1.8.1.2. Morphology and Identification 
A. Typical Organisms: The Enterobacteriaceae are short gram-negative 
rods that may form chains. Typical morphology is seen in growth on solid 
media in vitro, but morphology is highly variable in clinical specimens. 
Capsules are large and regular in Klebsiella, less so in Enterobacter, and 
uncommon in the other species (Blair et al 1970, Jawetz, et al 1995). 
 
B. Culture: Escherichia coli, and most of the other enteric bacteria form 
circular, convex, smooth colonies with distinct edges. Enterobacter 
colonies are similar but somewhat more mucoid. Klebsiella colonies are 
large and very mucoid and tend to coalesce with prolonged incubation. 
The salmonellae and shigellae produce colonies similar to Escherichia 
coli, but do not ferment lactose. Some strains of Escherichia coli, 
produce hemolysis on blood agar. 
C. Growth Characteristics: Carbohydrate fermentation patterns and the 
activity of amino acid decarboxylases and other enzymes are used in 
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biochemical differentiation. Some tests, eg, the production of indole from 
tryptophan, are commonly used in rapid identification systems, while 
others, eg. the Voges-Proskauer reaction (production of acetyl 
methylcarbinol from dextrose), are used less often. Culture on 
"differential" media that contain special dyes and carbohydrates (eg, 
eosin-methylene blue [EMB], MacConkey's, or deoxycholate medium 
distinguishes lactose-fermenting (colored) from non-lactose-fermenting 
colonies (nonpigmented) and may allow rapid presumptive identification 
of enteric bacteria (Blair et al 1970, Jawetz, et al 1995). 
1.8.1.3. Escherichia coli 
Escherichia coli typically produces positive tests for indole, lysine 
decarboxylase, and mannitol fermentation and produces gas from 
glucose. An isolate from urine can be quickly identified as Escherichia 
coli, by its hemolysis on blood agar, typical colonial morphology with an 
iridescent "sheen" on differential media such as EMB agar, and a 
positive spot indole test. Over 90% of Escherichia coli, isolates are 
positive for (3-glucuronidase using the substrate 4-methylumbelliferyl-P-
glu-curonide (MUG). Isolates from anatomic sites other than urine, with 
characteristic properties (above plus negative oxidase tests) often can 
be confirmed as Escherichia coli, with a positive MUG test (Blair et al 
1970, Jawetz, et al 1995). 
1.8.1.4. Klebsiella aerogenes 
Klebsiella aero-genes exhibit mucoid growth, large poly-saccharide 
capsules, and lack of motility, and they usually give positive tests for 
lysine decarboxylase and citrate. Most Enterobacter aero-genes give 
positive tests for motility, citrate, and ornithine decarboxylase and 
produce gas from glucose. Enterobacter aero-genes have small 
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capsules. Serratia produces DNase, lipase, and gelatinase. Klebsiella, 
Enterobacter, and Serratia usually give positive Voges-Proskauer 
reactions (Blair et al 1970, Jawetz, et al 1995). 
1.8.1.5. Proteus vulgaris  
Proteus vulgaris deaminate phenylalanine, are motile, grow on 
potassium cyanide medium (KCN), and ferment xylose. Proteus vulgaris 
move very actively by means of peritrichous flagella, resulting in 
"swarming" on solid media unless the swarming is inhibited by 
chemicals, eg, phenylethyl alcohol or CLED (cystine-lactose-electrolyte-
deficient) medium. Proteus vulgaris and Morganella morganii are urease-
positive, while Providencia species usually are urease-negative. The 
Proteus-Providencia group ferment lactose very slowly or not at all. 
Proteus mirabilis is more susceptible to antimicrobial drugs, including 
penicillins, than other members of the group (Blair et al 1970, Jawetz, et 
al 1995). 
1.8.1.6. Colicins (Bacteriocins), Toxins and Enzymes 
Many gram-negative organisms produce bacteriocins. These virus-like 
bactericidal substances are produced by certain strains of bacteria 
active against some other strains of the same or closely related species. 
Their production is controlled by plasmids. Colicins are produced by 
Escherichia coli, marcescins by Serratia, and pyocins by Pseudomonas. 
Bacteriocin-producing strains are resistant to their own bacteriocin; 
thus, bacteriocins can be used for "typing" of organisms (Blair et al 
1970, Jawetz, et al 1995). 
Most gram-negative bacteria possess complex lipopolysaccharides in 
their cell walls. These substances, endotoxins, have a variety of 
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pathophysiologic effects. Many gram-negative enteric bacteria also 
produce exotoxins of clinical importance.  
1.8.1.7. Diseases Caused by Enterobacteriaceae  
1.8.1.7.1. Causative Organisms 
Escherichia coli is a member of the normal intestinal flora. Other enteric 
bacteria (Proteus, Enterobacter, Klebsiella, Morganella species) are also 
found as members of the normal intestinal flora but are considerably less 
common than Escherichia coli. The enteric bacteria are sometimes 
found in small numbers as part of the normal flora of the upper 
respiratory and genital tracts. The enteric bacteria generally do not 
cause disease, and in the intestine they may even contribute to normal 
function and nutrition. When clinically important infections occur, they 
are usually caused by Escherichia coli, but the other enteric bacteria are 
causes of hospital-acquired infections and occasionally cause 
community-acquired infections. The bacteria become pathogenic only 
when they reach tissues outside of their normal intestinal or other less 
common normal flora sites. The most frequent sites of clinically 
important infection are the urinary tract, biliary tract, and other sites in 
the abdominal cavity, but any anatomic site (eg, bacteremia, prostate 
gland, lung, bone, meninges) can be the site of disease. Some of the 
enteric bacteria are opportunistic pathogens. When normal host 
defenses are inadequate—particularly in infancy or old age, in the 
terminal stages of other diseases, after immunosuppression, or with in-
dwelling venous or urethral catheters—localized clinically important 
infections can result, and the bacteria may reach the blood stream and 
cause sepsis (Blair et al 1970, Jawetz, et al 1995). 
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a. Escherichia coli  
Urinary tract infection- Escherichia coli is the most common cause of 
urinary tract infection and accounts for approximately 90% of first 
urinary tract infections in young women. The symptoms and signs 
include urinary frequency, dysuria, hematuria, and pyuria. Flank pain is 
associated with upper tract infection. None of these symptoms or signs 
is specific for Escherichia coli infection. Urinary tract infection can result 
in bacteremia with clinical signs of sepsis (Blair et al 1970, Jawetz, et al 
1995). 
Nephropathogenic- Escherichia coli typically produce a hemolysin. Most 
of the infections are caused by Escherichia coli with a small number of 0 
antigen types. K antigen appears to be important in the pathogenesis of 
upper tract infection. Pyelonephritis is associated with a specific type of 
pilus, P pilus, which binds to the P blood group substance. 
A. Escherichia coli associated diarrheal diseases- Escherichia coli that 
cause diarrhea are extremely common worldwide. These Escherichia 
coli are classified by the characteristics of their virulence properties 
(see below), and each group causes disease by a different 
mechanism..  
B. Sepsis- When normal host defenses are inadequate; Escherichia coli 
may reach the bloodstream and cause sepsis. Newborns may be 
highly susceptible to Escherichia coli sepsis because they lack IgM 
antibodies. Sepsis may occur secondary to urinary tract infections. 
C. Meningitis- Escherichia coli and group B streptococci are the leading 
causes of meningitis in infants. Approximately 75% of Escherichia coli 
from meningitis cases have the Kl antigen. This antigen cross-reacts 
with the group B capsular polysaccharide of N meningitidis. The 
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mechanism of virulence associated with the Kl antigen is not 
understood. 
a. Klebsiella spp  
The pathogenesis of disease caused by these groups of enteric gram-
negative rods is similar to that of the nonspecific factors in disease 
caused by Escherichia coli. 
Klebsiella pneumoniae is present in the respiratory tract and feces of 
about 5% of normal individuals. It causes a small proportion (about 3%) 
of bacterial pneumonias. Klebsiella pneumoniae can produce extensive 
hemorrhagic necrotising consolidation of the lung. It occasionally 
produces urinary tract infection and bacteremia with focal lesions in 
debilitated patients. Other enterics also may produce pneumonia. 
Klebsiella pneumoniae and Klebsiella oxytoca cause hospital-acquired 
infections. Two other klebsiellae are associated with inflammatory 
conditions of the upper respiratory tract: Klebsiella ozaenae has been 
isolated from the nasal mucosa in ozena, a fetid, progressive atrophy of 
mucous membranes: and Klebsiella rhinoscleromatis from 
rhinoscleroma, a destructive granuloma of the nose and pharynx (Blair et 
al 1970, Jawetz, et al 1995). 
c. Proteus spp  
Proteus-Proteus species produce infections in humans only when the 
bacteria leave the intestinal tract. They are found in urinary tract 
infections and produce bacteremia, pneumonia, and focal lesions in 
debilitated patients or those receiving intravenous infusions. Proteus 
mirabilis causes urinary tract infections and occasionally other 
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infections. Proteus vulgaris and Morganella morganii are important 
nosocomial pathogens. 
1.8.1.8. Treatment 
No single specific therapy is available. The sulfon-amides, ampicillin, 
cephalosporins, chloramphenicol, tetracyclines, and aminoglycosides 
have marked antibacterial effects against the enterics, but variation in 
susceptibility is great, and laboratory tests for antibiotic susceptibility 
are essential. Multiple drug resistance is common and is under the 
control of transmissible plasmids. 
1.8.1.9. Epidemiology, Prevention and Control 
The enteric bacteria establish themselves in the normal intestinal tract 
within few days after birth and from then on constitute a main portion of 
the normal aerobic (facultative anaerobic) microbial flora. Escherichia 
coli is the prototype. Enterics found in water or milk is accepted as proof 
of fecal contamination from sewage or other sources (Blair et al 1970, 
Jawetz, et al 1995). 
Control measures are not feasible as far as the normal endogenous flora 
is concerned. Enteropathogenic Escherichia coli serotypes should be 
controlled like salmonellae. Some of the enterics constitute a major 
problem in hospital infection. It is particularly important to recognise that 
many enteric bacteria are "opportunists" which cause illness when they 
are introduced into debilitated patients. Within hospitals or other 
institutions, these bacteria commonly are transmitted by personnel, 
instruments, or parenteral medications. Their control depends on hand 
washing, rigorous asepsis, sterilization of equipment, disinfection, 
restraint in intravenous therapy, and strict precautions in keeping the 
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urinary tract sterile (ie, closed drainage) (Blair et al 1970, Jawetz, et al 
1995). 
1.8.2. Staphylococci 
The Staphylococci are gram-positive spherical cells, usually arranged in 
grape-like irregular clusters. They grow readily on many types of media 
and are active metabolically, fermenting carbohydrates and producing 
pigments that vary from white to deep yellow. Some are members of the 
normal flora of the skin and mucous membranes of humans; others 
cause suppuration, abscess formation, a variety of pyogenic infections, 
and even fatal septicemia. The pathogenic Staphylococci often hemolyse 
blood, coagulate plasma, and produce a variety of extracellular enzymes 
and toxins. The most common type of food poisoning is caused by a heat-
stable staphylococcai enterotoxin. Staphylococci rapidly develop 
resistance to many antimicrobial agents and present difficult therapeutic 
problems (Blair et al 1970, Jawetz, et al 1995). 
The genus Staphylococcus has at least 30 species. The three main 
species of clinical importance are Staphylococcus aureus, 
Staphylococcus epidermidis, and Staphylococcus saprophyticus. 
Staphylococcus aureus is coagulase-positive, which differentiates it 
from the other species. Staphylococcus aureus. is a major pathogen for 
humans. Almost every person will have some type of Staphylococcus 
aureus infection during a lifetime, ranging in severity from food 
poisoning or minor skin infections to severe life-threatening infections. 
The coagulase-negative Staphylococci are normal human flora and 
sometimes cause infection, often associated with implanted appliances 
and devices, especially in very young, old, and immunocompromised 
patients. Approximately 75% of these infections caused by coag-ulase-
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negative Staphylococci are due to S. epidermidis; infections due to 
Staphylococcus warneri, Staphylococcus hominis, and other species are 
less common. S. saprophyticus is a relatively common cause of urinary 
tract infections in young women. Other species are important in 
veterinary medicine (Blair et al 1970, Jawetz, et al 1995). 
1.8.2.1. Morphology and Identification  
Typical Organisms: Staphylococci are spherical cells about 1 µm in 
diameter arranged in irregular clusters. Single cocci, pairs, tetrads, and 
chains are also seen in liquid cultures. Young cocci stain strongly gram-
positive; on aging, many cells become gram-negative. Staphylococci are 
nonmotile and do not form spores. Under the influence of drugs like 
penicillin, Staphylococci are lysed (Blair et al 1970, Jawetz, et al 1995).  
Culture: Staphylococci grow readily on most bacteriologic media under 
aerobic or microaerophilic conditions. They grow most rapidly at 37 °C 
but form pigment best at room temperature (20-25 °C). Colonies on solid 
media are round, smooth, raised, and glistening. S aureus usually forms 
grey to deep golden yellow colonies. Staphylococcus epidermidis 
colonies usually are grey to white on primary isolation; many colonies de-
velop pigment only upon prolonged incubation. No pigment is produced 
anaerobically or in broth. Various degrees of hemolysis are produced by 
Staphylococcus aureus and occasionally by other species (Blair et al 
1970, Jawetz, et al 1995). 
Growth Characteristics: The Staphylococci produce catalase, which 
differentiates them from the streptococci. Staphylococci slowly ferment 
many carbohydrates including lactose, producing lactic acid but not gas. 
Proteolytic activity varies greatly from one strain to another. Pathogenic 
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Staphylococci produce many extracellular substances (Blair et al 1970, 
Jawetz, et al 1995). 
Staphylococci are relatively resistant to drying, heat (they withstand 50 
°C for 30 minutes), and 9% sodium chloride but are readily inhibited by 
certain chemicals, eg, 3% hexachlorophene. Staphylococci are variably 
sensitive to many antimicrobial drugs. Resistance falls into several 
classes (Blair et al 1970, Jawetz, et al 1995): 
(1) β-lactamase production is common, is under plasmid control, and 
makes the organisms resistant to many penicillins (penicillin G, 
ampicillin, ticarcillin, and similar drugs). The plasmids are transmitted 
by-transduction and perhaps also by conjugation.  
(2) Resistance to nafcillin (and to methicillin and oxacillin) is independent 
of β -lactamase production. The genes for nafcillin resistance reside on 
the chromosome and are variably expressed. The mechanism of nafcillin 
resistance is related to the lack or inaccessibility of certain penicillin-
binding proteins (PBPs) in the organisms.  
(3) "Tolerance" implies that Staphylococci inhibited by a drug but not 
killed by it, i.e., there is very large difference between minimal inhibitory 
and minimal lethal concentrations of an antimicrobial drug. Tolerance 
can at times be attributed to a lack of activation of autolytic enzymes in 
the cell wall.  
(4) Plasmids can also carry genes for resistance to tetracyclines, 
erythromycins, aminoglycosides, and other drugs. Staphylococci have 
remained susceptible to vancomycin (Blair et al 1970, Jawetz, et al 
1995). 
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 D. Variation: A culture of Staphylococci contains some bacteria that 
differ from the bulk of the population in expression of colony 
characteristics (colony size, pigment, hemolysis), in enzyme elaboration, 
in drug resistance, and in pathogenicity. In vitro, the expression of such 
characteristics is influenced by growth conditions: When nafcillin-
resistant S. aureus is incubated at 37 °C on blood agar, one in 107 
organisms expresses nafcillin resistance; when it is incubated at 30 °C 
on agar containing 2-5% sodium chloride, one in 103 organisms 
expresses nafcillin resistance (Blair et al 1970, Jawetz, et al 1995). 
1.8.2.2. Toxins and Enzymes 
Staphylococci can produce disease both through their ability to multiply 
and spread widely in tissues and through their production of many 
extracellular substances. Some of these substances are enzyme 
(Catalase; Coagulase, hyaluronidase; staphylokinase proteinases; 
lipases; and β-lactamase). Others are considered to be toxins (Exotoxins; 
Leukocidin; Exfoliative; Toxic Shock Syndrome Toxin; and Enterotoxins) 
(Blair et al 1970, Jawetz, et al 1995). 
1.8.2.3. Diseases Caused by Staphylococci  
Staphylococci, particularly Staphylococcus epidermidis, are members of 
the normal flora of the human skin and respiratory and gastrointestinal 
tracts. Nasal carriage of Staphylococcus aureus occurs in 40-50% of 
humans. Staphylococci are also found regularly on clothing, bed linens, 
and other fomites in human environments. 
The pathogenic capacity of a given strain of Staphylococcus aureus is 
the combined effect of extracellular factors and toxins together with the 
invasive properties of the strain. At one end of the disease spectrum is 
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staphylococcal food poisoning, attributable solely to the ingestion of 
preformed enterotoxin; at the other end are staphylococcal bacteremia 
and disseminated abscesses in all organs. The potential contribution of 
the various extracellular substances in pathogenesis is evident from the 
nature of their individual actions (Blair et al 1970, Jawetz, et al 1995). 
Pathogenic, invasive Staphylococcus. aureus produces coagulase and 
tends to produce a yellow pigment and to be hemolytic. Nonpathogenic, 
noninvasive Staphylococci such as Staphylococcus epidermidis are 
coagulase-negative and tend to be nonhemolytic. Such organisms rarely 
produce suppuration but may infect orthopedic or cardiovascular 
prostheses or cause disease in immunosuppressed persons. 
Staphylococcus saprophyticus is typically nonpigmented, novobiocin-
resistant, and nonhemolytic; it causes urinary tract infections in young 
women (Blair et al 1970, Jawetz, et al 1995). 
The prototype of a staphylococcal lesion is the furuncle or other 
localized abscess. Groups of Staphylococcus aureus established in a 
hair follicle lead to tissue necrosis (dermonecrotic factor). Coagulase is 
produced and coagulates fibrin around the lesion and within the lym-
phatics, resulting in formation of a wall that limits the process and is 
reinforced by the accumulation of inflammatory cells and, later, fibrous 
tissue. Within the center of the lesion, liquefaction of the necrotic tissue 
occurs (enhanced by delayed hypersensitivity), and the abscess "points" 
in the direction of least resistance. Drainage of the liquid center necrotic 
tissue is followed by slow filling of the cavity with granulation tissue and 
eventual healing (Blair et al 1970, Jawetz, et al 1995). 
Focal suppuration (abscess) is typical of staphylococcal infection. From 
any one focus, organisms may spread via the lymphatics and 
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bloodstream to other parts of the body. Suppuration within veins, 
associated with thrombosis, is a common feature of such dissemination. 
In osteomyelitis, the primary focus of S. aureus growth is typically in a 
terminal blood vessel of the metaphysis of a long bone, leading to 
necrosis of bone and chronic suppuration. Staphylococcus aureus may 
cause pneumonia, meningitis, empyema, endocarditis, or sepsis with 
suppuration in any organ. Staphylococci of low invasiveness are involved 
in many skin infections (eg, acne, pyoderma, or impetigo). Anaerobic 
cocci (Peptostrep tococcus) participate in mixed anaerobic infections 
(Blair et al 1970, Jawetz, et al 1995). 
Staphylococci also cause disease through the elaboration of toxins, 
without apparent invasive infection. Bullous exfoliation, the scalded skin 
syndrome, is caused by the production of exfoliative toxin. Toxic shock 
syndrome is associated with toxic shock syndrome toxin-1 (TSST-1) 
(Blair et al 1970, Jawetz, et al 1995). 
A localised staphylococcal infection appears as a "pimple," hair follicle 
infection, or abscess. There is usually an intense, localised, painful 
inflammatory reaction that undergoes central suppuration and heals 
quickly when the pus is drained. The wall of fibrin and cells around the 
core of the abscess tends to prevent spread of the organisms and should 
not be broken down by manipulation or trauma (Blair et al 1970, Jawetz, 
et al 1995). 
Staphylococcus aureus infection can also result from direct 
contamination of a wound, eg, postoperative staphylococcal wound 
infection or infection following trauma (chronic osteomyelitis subsequent 
to an open fracture, meningitis following skull fracture). 
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If Staphylococcus aureus disseminates and bacteremia ensues, 
endocarditis, acute hematogenous osteomyelitis, meningitis, or 
pulmonary infection can result. The clinical presentations resemble 
those seen with other blood stream infections. Secondary localization 
within an organ or system is accompanied by the symptoms and signs of 
organ dysfunction and intense focal suppuration (Blair et al 1970, 
Jawetz, et al 1995). 
Food poisoning due to staphylococcal enterotoxin is characterised by a 
short incubation period (1-8 hours' violent nausea, vomiting, and 
diarrhea; and rapid convalescence. There is no fever. 
Toxic shock syndrome is manifested by an abrupt onset of high fever, 
vomiting, diarrhea, myalgias, a scarlatiniform rash, and hypotension with 
cardiac and renal failure in the most severe cases. It often occurs within 
5 days after the onset of menses in young women who use tampons, but 
it also occurs in children or in men with staphylococcal wound 
infections. The syndrome can recur. Toxic shock syndrome-associated 
Staphylococcus aureus can be found in the vagina, on tampons in 
wounds or other localised infections, or in the throat but virtually never 
in the bloodstream (Blair et al 1970, Jawetz, et al 1995). 
1.8.2.4. Treatment 
Most persons harbor staphylococci on the skin and in the nose or throat. 
Even if the skin can be cleared of staphylococci (eg, in eczema), 
reinfection by droplets will occur almost immediately. Because 
pathogenic organisms are commonly spread from one lesion (eg, a 
furuncle) to other areas of the skin by fingers and clothing, scrupulous 
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local antisepsis is important to control recurrent furunculosis (Blair et al 
1970, Jawetz, et al 1995). 
Serious multiple skin infections (acne, furunculosis) occur most often in 
adolescents. Similar skin infections occur in patients receiving 
prolonged courses of corticosteroids. In acne, lipases of staphylococci 
and corynebacteria liberate fatty acids from lipids and thus cause tissue 
irritation. Tetracyclines are used for long-term treatment (Blair et al 
1970, Jawetz, et al 1995). 
Abscesses and other closed suppurating lesions are treated by 
drainage, which is essential, and antimicrobial therapy. Many 
antimicrobial drugs have some effect against staphylococci in vitro. 
However, it is difficult to eradicate pathogenic staphylococci from 
infected persons, because the organisms rapidly develop resistance to 
many antimicrobial drugs and the drugs cannot act in the central 
necrotic part of a suppurative lesion. It is also difficult to eradicate the S. 
aureus carrier state (Blair et al 1970, Jawetz, et al 1995). 
Acute hematogenous osteomyelitis responds well to antimicrobial drugs. 
In chronic and recurrent osteomyelitis, surgical drainage and removal of 
dead bone is accompanied by long-term administration of appropriate 
drugs, but eradication of the infecting staphylococci is difficult. 
Hyperbaric oxygen and the application of vascularised myocutaneous 
flaps have aided healing in chronic osteomyelitis (Blair et al 1970, 
Jawetz, et al 1995). 
Bacteremia, endocarditis, pneumonia, and other severe infections due to 
Staphylococcus aureus require prolonged intravenous therapy with a (β-
lactamase-resistant penicillin. Vancomycin is often reserved for use with 
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nafcillin-resistant staphylococci. If the infection is found to be due to 
non-(β-lactamase-producing S. aureus, penicillin G is the drug of choice, 
but only a small percentage of Staphylococcus aureus strains are 
susceptible to penicillin G (Blair et al 1970, Jawetz, et al 1995). 
Staphylococcus epidermidis infections are difficult to cure because they 
occur in prosthetic devices where the bacteria can sequester 
themselves from the circulation and thus from antimicrobial drugs. 
Staphylococcus epidermidis is more often resistant to antimicrobial 
drugs than is Staphylococcus aureus; approximately 75% of 
Staphylococcus epidermidis strains are nafcillin-resistant (Blair et al 
1970, Jawetz, et al 1995). 
Because of the frequency of drug-resistant strains, meaningful 
staphylococcal isolates should be tested for antimicrobial susceptibility 
to help in the choice of systemic drugs. Resistance to drugs of the 
erythromycin group tends to emerge so rapidly that these drugs should 
not be used singly for treatment of chronic infection. Drug resistance (to 
penicillins, tetracyclines, aminoglycosides, erythromycins, etc) deter-
mined by plasmids can be transmitted among staphylococci by 
transduction and perhaps by conjugation (Blair et al 1970, Jawetz, et al 
1995). 
Penicillin G-resistant Staphylococcus aureus strains from clinical 
infections always produce penicillinase. They now constitute about 90% 
of Staphylococcus aureus isolates in communities in the USA. They are 
often susceptible to lactamase-resistant penicillins, cephalosporins, or 
vancomycin. Nafcillin resistance is independent of β-lactamase 
production, and its clinical incidence varies greatly in different countries 
and at different times. The selection pressure of (β-lactamase-resistant 
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antimicrobial drugs may not be the sole determinant for resistance to 
these drugs: For example, in Denmark, nafcillin-resistant S. aureus 
comprised 40% of isolates in 1970 and only 10% in 1980, without notable 
changes in the use of nafcillin or similar drugs. In the USA, nafcillin-
resistant S. aureus accounted for only 0.1% of isolates in 1970 but in the 
1990s constituted 10-30% of isolates from infections in some hospitals. 
Vancomycin remains the most widely effective drug against 
staphylococci (  etal 1970, Jawetz, et al 1995). 
1.8.2.5. Epidemiology and Control 
Staphylococci are ubiquitous human parasites. The chief sources of 
infection are shedding human lesions, fomites contaminated from such 
lesions, and the human respiratory tract and skin. Contact spread of in-
fection has assumed added importance in hospitals, where a large 
proportion of the staff and patients carry antibiotic-resistant 
staphylococci in the nose or on the skin. Although cleanliness, hygiene, 
and aseptic management of lesions can control the spread of 
staphylococci from lesions, few methods are available to prevent the 
wide dissemination of staphylococci from carriers. Aerosols (eg, glycols) 
and ultraviolet irradiation of air have little effect (Blair et al 1970, Jawetz, 
et al 1995). 
In hospitals, the areas at highest risk for severe staphylococcal 
infections are the newborn nursery, intensive care units, operating 
rooms, and cancer chemotherapy wards. Massive introduction of 
“epidemic” pathogenic Staphylococcus aureus into these areas may 
lead to serious clinical disease. Personnel with active Staphylococcus 
aureus Iesions and carriers may have to be excluded from these areas. 
In such individuals, the application of topical antiseptics (eg, 
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chlorhexidine or bacitracin cream) to nasal or perineal carriage sites 
may diminish shedding of dangerous organisms. Rifampin coupled with a 
second oral antistaphylococcal drug sometimes provides long-term 
suppression and possibly cure of nasal carriage; this form of therapy is 
usually reserved to major problems of staphylococcal carriage, because 
staphylococci can rapidly develop resistance to rifampin. Antiseptics 
such as hexachlorophene used on the skin of newborns diminish 
colonisation by staphylococci, but toxicity prevents their widespread 
(Blair et al 1970, Jawetz, et al 1995). 
1.8.3. Pseudomonas Group 
The Pseudomonas group are gram-negative, motile, aerobic rods some 
of which produce water-soluble pigments. Pseudomonads occur widely 
in soil, water, plants, and animals. Pseudomonas aeruginosa is 
frequently present in small numbers in the normal intestinal flora and on 
the skin of humans and is the major pathogen of the group. Other 
Pseudomonas species infrequently cause disease. The classification of 
pseudomonads is based on RNA/DNA homology and common culture 
characteristics (Blair et al 1970, Jawetz, et al 1995).  
Pseudomonas aeruginosa is widely distributed in nature and is 
commonly present in moist environments in hospitals. It can colonise 
normal humans, in whom it is a saprophyte. It causes disease in humans 
with abnormal host defences (Blair e tal 1970, Jawetz, et al 1995). 
1.8.3.1. Morphology and Identification 
A. Typical Organisms: Pseudomonas aeruginosa is motile and rod-
shaped, measuring about 0.6 X 2 µm. It is gram-negative and occurs as 
single bacteria, in pairs, and occasionally in short chains. 
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B. Culture: Pseudomonas aeruginosa is an obligate aerobe that grows 
readily on many types of culture media, sometimes producing a sweet or 
grape-like odor. Some strains hemolyse blood. Pseudomonas aeruginosa 
forms smooth round colonies with a fluorescent greenish color. It often 
produces the nonfluorescent bluish pigment pyocyanin, which diffuses 
into the agar. Other Pseudomonas species do not produce pyocyanin. 
Many strains of Pseudomonas aeruginosa also produce the fluorescent 
pigment pyoverdin, which gives a greenish color to the agar. Some 
strains produce the dark red pigment pyorubin or the black pigment 
pyomelanin. 
Pseudomonas aeruginosa in a culture can produce multiple colony 
types, giving the impression of a culture of mixed species of bacteria. 
Pseudomonas aeruginosa from different colony types may also have 
different biochemical and enzymatic activities and different antimicrobial 
susceptibility patterns. Cultures from patients with cystic fibrosis often 
yield Pseudomonas aeruginosa organisms that form very mucoid 
colonies as a result of overproduction of alginate, an exopolysaccharide. 
C. Growth Characteristics: Pseudomonas aeruginosa grows well at 37-
42 °C; its growth at 42 °C helps differentiate it from other Pseudomonas 
species. It is oxidase-positive. It does not ferment carbohydrates, but 
many strains oxidise glucose. Identification is usually based on colonial 
morphology, oxidase positivity, the presence of characteristic pigments, 
and growth at 42 °C. Differentiation of Pseudomonas aeruginosa from 
other pseudomonads on the basis of biochemical activity requires 
testing with a large battery of substrates (Blair et al 1970, Jawetz, et al 
1995). 
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1.8.3.2. Enzymes and Toxins 
Many strains of Pseudomonas aeruginosa produce exotoxin A, which 
causes tissue necrosis and is lethal for animals when injected in purified 
form. The toxin blocks protein synthesis by a mechanism of action 
identical to that of diphtheria toxin, though the structures of the two 
toxins are not identical. Antitoxins to exotoxin A are found in some human 
sera, including those of patients who have recovered from serious 
Pseudomonas aeruginosa infections (Blair et al 1970, Jawetz, et al 1995). 
1.8.3.3. Pathogenesis and Clinical Findings 
Pseudomonas aeruginosa is pathogenic only when introduced into areas 
devoid of normal defenses, eg, when mucous membranes and skin are 
disrupted by direct tissue damage; when intravenous or urinary 
catheters are used; or when neutropenia is present, as in cancer 
chemotherapy. The bacterium attaches to and colonises the mucous 
membranes or skin, invades locally, and produces systemic disease. 
These processes are promoted by the pili, enzymes, and toxins 
described above. Lipopolysaccharide plays a direct role in causing 
fever, shock, oliguria, leukocytosis and leukopenia, disseminated 
intravascular coagulation, and adult respiratory distress syndrome (Blair 
et al 1970, Jawetz, et al 1995). 
Pseudomonas aeruginosa (and other species, eg, Pseudomonas 
cepacia, Pseudomonas putida) is resistant to many antimicrobial agents 
and therefore becomes dominant and important when more susceptible 
bacteria of the normal flora are suppressed. 
Pseudomonas aeruginosa produces infection of wounds and burns, 
giving rise to blue-green pus; meningitis, when introduced by lumbar 
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puncture; and urinary tract infection, when introduced by catheters and 
instruments or in irrigating solutions. Involvement of the respiratory 
tract, especially from contaminated respirators, results in necrotising 
pneumonia. The bacterium is often found in mild otitis extema in 
swimmers. It may cause invasive (malignant) otitis extema in diabetic 
patients. Infection of the eye, which may lead to rapid destruction of the 
eye, occurs most commonly after injury or surgical procedures. In 
infants or debilitated persons, Pseudomonas aeruginosa may invade the 
bloodstream and result in fatal sepsis; this occurs commonly in patients 
with leukemia or lymphoma who have received antineoplastic drugs or 
radiation therapy and in patients with severe burns. In most 
Pseudomonas aeruginosa infections, the symptoms and signs are 
nonspecific and are related to the organ involved. Occasionally, 
verdoglobin (a breakdown product of hemoglobin) or fluorescent 
pigment can be detected in wounds, burns, or urine by ultraviolet 
fluorescence. Hemorrhagic necrosis of skin occurs often in sepsis due to 
Pseudomonas aeruginosa; the lesions, called ecthyma gangrenosum, 
are surrounded by erythema and often do not contain pus. Pseudomonas 
aeruginosa can be seen on Gram-stained specimens from ecthyma 
lesions, and cultures are positive. Ecthyma gangrenosum is uncommon 
in bacteremia due to organisms other than Pseudomonas aeruginosa 
(Blair et al 1970, Jawetz, et al 1995). 
1.8.3.4. Treatment 
Clinically significant infections with Pseudomonas aeruginosa should not 
be treated with single-drug therapy, because the success rate is low with 
such therapy and because the bacteria can rapidly develop resistance 
when single drugs are employed. A penicillin active against 
Pseudomonas aeruginosa —ticarcillin, mezlocillin, and piperacillin—is 
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used in combination with an aminoglycoside, usually gentamicin, 
tobramycin, or amikacin. Other drugs active against Pseudomonas 
aeruginosa include aztreonam, imipenem, and the newer quinolones, 
including ciprofloxacin. Of the newer cephalosporins, ceftazidime and 
cefoperazone are active against Pseudomonas aeruginosa; ceftazidime 
is used in primary therapy of Pseudomonas aeruginosa infections. The 
susceptibility patterns of Pseudomonas aeruginosa vary geographically, 
and susceptibility tests should be done as an adjunct to selection of an-
timicrobial therapy (Blair et al 1970, Jawetz, et al 1995). 
1.8.3.5. Epidemiology and Control 
Pseudomonas aeruginosa is primarily a nosocomial pathogen, and the 
methods for control of infection are similar to those for other nosocomial 
pathogens. Since Pseudomonas thrives in moist environments, special 
attention should be paid to sinks, water baths, showers, hot tubs, and 
other wet areas. For epidemiologic purposes, strains can be typed by 
pyocins and by lipopolysaccharide immunotypes. Vaccine from 
appropriate types administered to high-risk patients provides some 
protection against Pseudomonas sepsis. Such treatment has been used 
experimentally in patients with leukemia, burns, cystic fibrosis, and 
immunosuppression (Blair et al 1970, Jawetz, et al 1995). 
1.8.4. Bacillus Species 
The genus Bacillus includes large aerobic, gram-positive rods occurring 
in chains. Most members of this genus are saprophytic organisms 
prevalent in soil, water, and air and on vegetation, such as Bacillus 
cereus and Bacillus subtilis. Some are insect pathogens. Bacillus cereus 
can grow in foods and produce an enterotoxin or an emetic toxin and 
cause food poisoning. Such organisms may occasionally produce dis-
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ease in immunocompromised humans (eg, meningitis, endocarditis, 
endophthalmitis, conjunctivitis, or acute gastroenteritis). Bacillus 
anthracis, which causes anthrax, is the principal pathogen of the genus 
(Blair et al 1970, Jawetz, et al 1995). 
 
 
1.8.4.1. Morphology and Identification 
A. Typical Organisms: The typical cells, measuring 1 X 3-4 µm, have 
square ends and are arranged in long chains; spores are located in the 
center of the nonmotile bacilli. 
B. Culture: Colonies of Bacillus anthracis are round and have a "cut 
glass" appearance in transmitted light. Hemolysis is uncommon with 
Bacillus anthracis but common with the saprophytic bacilli. Gelatin is 
liquefied, and growth in gelatin stabs resembles an inverted fir tree. 
C. Growth Characteristics: The saprophytic bacilli utilize simple sources 
of nitrogen and carbon for energy and growth. The spores are resistant 
to environmental changes, withstand dry heat and certain chemical 
disinfectants for moderate periods, and persist for years in dry earth. 
Animal products contaminated with anthrax spores (eg, hides, bristles, 
hair, wool, bone) can be sterilized only by autoclaving (Blair et al 1970, 
Jawetz, et al 1995). 
1.8.4.2. Bacillus Cereus 
Food poisoning caused by Bacillus cereus has two distinct forms, the 
emetic type and the diarrheal type associated with meat dishes and 
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sauces. Bacillus cereus produces toxins that cause disease which is 
more an intoxication than a food-home infection. The emetic form is 
manifested by nausea, vomiting, abdominal cramps, and occasionally 
diarrhea and is self-limiting, with recovery occurring within 24 hours. It 
begins 1-5 hours after ingestion of rice and occasionally pasta dishes. B 
cereus is a soil organism that commonly con-laminates rice. When large 
amounts of rice are cooked and allowed to cool slowly, the B cereus 
spores germinate and the vegetative cells produce the toxin during log-
phase growth or during sporulation. The diarrheal form has an 
incubation period of 1-24 hours and is manifested by profuse diarrhea 
with abdominal pain and cramps; fever and vomiting are uncommon. The 
enterotoxin may be preformed in the food or produced in the intestine. 
The presence of B cereus in a patient's stool is not sufficient to make a 
diagnosis of B cereus disease, since the bacteria may be present in 
normal stool specimens; a concentration of 105 bacteria or more per 
gram of food is considered diagnostic (Blair et al 1970, Jawetz, et al 
1995). 
Bacillus cereus is an important cause of eye infections, severe keratitis, 
endophthalmitis, and panophthalmitis. Typically, the organisms are 
introduced into the eye by foreign bodies associated with trauma. B 
cereus has also been associated with localized infections and with 
systemic infections, including endocarditis, meningitis, osteomyelitis, 
and pneumonia; the presence of a medical device or intravenous drug 
use predisposes to these infections. 
Other Bacillus species are rarely associated with human disease. It is 
difficult to differentiate superficial contamination with Bacillus from 
genuine disease caused by the organism. Five Bacillus species (Bacillus 
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thuringiensis, Bacillus popilliae, Bacillus sphaericus, Bacillus larvae, and 
Bacillus lentifnorbus) are pathogens for insects, and some have been 
used as commercial insecticides (Blair et al 1970, Jawetzet al. 1995). 
1.8.5. Methicillin-resistant Staphylococcus 
aureus (MRSA) 
Enteric bacterial infection caused by resistant strains of Staphylococcus 
aureus , Eschrichia coli, Shigella and other bacteria are becoming more 
and more problematic and of major public health problem in both 
developed and developing countries (Livermore, 1995, Westh et al., 
2004). Infections with MRSA occur due to indiscriminate use of 
commercial antimicrobial drugs commonly employed in the treatment of 
infectious diseases and due to the poor hygienic conditions in both 
hospital and community, which is more prevalent in developing 
countries. These infections in many cases lead needlessly to deaths 
especially among the elderly. These deaths lead to huge bills of 
compensations that financially cripple hospitals (Parekh, and Chanda 
2007).  
In the past, mutation was the only known cause of resistance of bacteria 
to drugs. However, it was reported that multi-drug-resistant pathogens 
are on the rise, which was attributed to plasmid-mediated (Jones et al., 
2004), where β-lactamases continues to be the leading cause of 
resistance to β-lactam antibiotics in Gram- positive bacteria  
(Staphylococcus aureus  and vancomycin resistant enterococci) and 
Gram- negative bacteria (members of enterobacteriaceae producing 
plasmid-mediated extended spectrum β-lactamase (ESbL)) (Bradford, 
2001).  Resistance to β-lactam antibiotics was observed in other bacteria 
including Pseudomonas aeruginosa, Mycobacterium tuberculosis 
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(Medeiros, 1997; Sajduda et al., 1998), Eschrichia coli and other 
members of enterobacteriaceae (Wang et al., 2003; Cheung et al., 2005). 
Therefore, search for new antimicrobials to combat infectious diseases 
caused by multidrug-resistant bacteria including fast-spreading ESbL-
producing enteric bacteria is urgently needed.  
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2. Materials and Methods  
2.1. Materials 
Chemicals, reagents, chemotherapeutic agents, Culture media, 
Equipment and Instruments and Bacterial micro-organisms used in this 
study and their suppliers are itemised in the tables bellow: 
Table 1: Chemicals and Reagents 
 
Chemical Supplier 
Amyl Alcohol The British Drug House UK 
Chloroform S.D. Fine-Chem. Ltd., Mumbai 
Crystal violet The British Drug House UK 
D (-) Glucose anhydrous Park, Scientific Ltd., UK 
D (4-) Lactose Park, Scientific Ltd., UK 
D (-) Mannitol extra pure Kiran Light Lab. 
Ethylenediamine tetra-acetic acid The British Drug House, UK 
Emulsifying wax Medex, UK 
Halothane ICI Ltd., India 
Hydrochloric acid The British Drug House, UK 
Hydrogen peroxide Bell, sons & Co., UK  
Immersion oil The British Drug House, UK 
Iodine Hopkins & Williams Ltd.  
Kovac's reagent B.G.H Chemicals, Japan 
Lactophenol cotton blue The British Drug House, UK 
LanolineB.P.  Sukani Enterprises, India 
Liquid paraffin BP Bell, sons & Co., UK 
Methanol Scharlu, Spain 
Methyl Red Oxoid, Ltd. 
Oxidase John baker Inc., USA 
Peptone Oxoid, Ltd. 
Petroleum Jelly B.P. Bogdany, Hungary 
Phenol Red The British Drug House, UK 
Polyethylene glycol (PEG) Flukp AG Chemische Fabrik 
Safranin Red The British Drug House, UK 
Sodium Chloride The British Drug House, UK 
Sucrose AR S.D. Fine-Chem. Ltd., Mumbai 
Urea Oxoid, Ltd. 
Petroleum Ether The British Drug House, UK 
Benzene The British Drug House, UK 
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Table 2: Chemotherapeutic agents 
 
Agent Batch No Supplier 
Benzylpenicillin 111472E Alembic Ltd, India 
Gentamycin 061108 Shaphar. Shanghai, China 
Ceftriaxone KF-610 Kilitch Drugs (India) Ltd. Thane, India 
Erythromycin  xxxx 
 
Table 3: Culture media 
 
Culture Supplier 
Blood Khartoum Hospital, Sudan 
Blood agar base Mast group Ltd., UK  
DNase media Plasmatec Lab Ltd., UK 
K.LA. media Mast group Ltd., UK 
Koser citrate medium Oxoid Ltd. 
Mac Conkey agar Scharlu, Spain 
Mannitol Salt agar Oxoid Ltd.  
Nutrient agar Scharlu, Spain 
Nutrient broth Scharlu, Spain 
Sabouraud Dextrose agar Plasmatec Lab. Ltd., UK 
Urea agar base Oxoid Ltd. 
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Table 4: Equipment and Instruments 
 
Equipment Supplier 
   Autoclave Baird & Tatlock Ltd. 
Balance A & D Company Ltd. 
Centrifuge Braun, Centrifuge PLC series 
Colony counter Anderman colony counter, UK. 
Glass ware Griffin & George Ltd. 
Hot air oven Nuve FN 500, Turkey 
Incubator                         Heraeus 
Microscope  Olympus CH-2, Japan 
Rota-vap Buchi, Switzerland 
Soxhiet Grant Instruments Ltd. 
Water bath Fisher scientific, USA 
 
 
Table 5: Bacterial micro-organisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacterial organism Code 
Bacillus subtilis  NCTC 8236 
Staphylococcus aureus   ATCC 25923 
Escherichia coli ATCC 25922  
Pseudomonas aeruginosa          ATCC 27853 
Klebsiella spp ATCC 35657 
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Table 6: Clinical Bacterial Organisms from  
Wounds and Abscesses of Adult Patients (Khartoum Hospital, Sudan) 
 
 
 
 
  
Bacterial Oraganism Numbers 
(%) 
Escherichia coli 20 
Pseudomonas aeruginosa 20 
Proteus vulgaris 18 
Klebseilla sp. 17 
Staphylococcus aureus  18 
Methicillin-resistant Staphylococcus 
aureus (MRSA)  
7 
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Table 7: Medicinal Plants selected for the study 
 
 
Latin name Arabic name English name 
Piper cubeba سوﺮﻌﻟا ﺐﺣ , ﺔَﺑﺎَﺒَآ Jawa peppercorn 
Anogussus leiocapus ﺐﺤﺼﻟا Axlewood tree 
Biota orientalis   ﺔﺼﻔﻌﻟا ,  ﺎﻳﻮﺜﻟا Eastern red 
Punica granatum  (Bark)   نﺎﻣﺮﻟا Pomegranate 
Punica granatum  (Wood)  نﺎﻣﺮﻟا Pomegranate 
Calendula arvensis ﻩﻮﻨﺤﻟا Field marigold 
Salvia officinalis ﺔﻴﻤﻳﺮﻣ Garden sage 
Nauclia latifolia ةدوﺪﻣﺮآ Pin cushion tree 
Cissus petiolata ﺮﺠﺤﻟا قﺮﻋ Bitter Aple and Bitter Groud 
Petasties hybriduss L. ﺖﻬﻜﻓ Butterbur 
Acorus calamus   رﺬﻟاﺮﻳﻩ Sweet Flag 
Ferula Asafoetida ﻟاﺖﻴِﺘْﻠَﺤ devil's dung 
Moringa perigrina  ،ﺮﺴﻴﻟا قاواﺮﻟا ةﺮﺠﺷ Drum-stick tree 
2.2. Methods 
2.2.1.  Plant materials 
The 12 medicinal plants used in this study, their botanical names, 
synonyms, families, morphological parts used, vernacular names and 
uses are shown in Table 7. These plants were obtained from local 
herbalists, Omdurman and Khartoum Souks (Markets). Local herbalists 
provided useful information including the description of the studied 
plants habitat, their local names, traditional method of preparing the 
herbal potions, the ailments they claim to cure and the methods of their 
applications.  
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The plants were identified and authenticated by the Department of 
Botany, University of Khartoum and the Medicinal and Aromatic Plants 
Research Institute.  
Ten grams sample of each of the 12 studied plants (Table 7) were taken, 
powdered and extracted and then they were screened for their 
antibacterial activity. 
2.2.2. Preparation of the crude extracts 
 
a. Continuous extraction 
 
Each of the powdered plant material samples (10 g) was extracted by 
Benzene, Chloroform and Methanol consecutively.  Firstly, the plant 
material sample was exhaustively extracted by benzene in a Soxhlet 
apparatus. The process took in average 24 hours. The benzene extracts 
were filtered and evaporated under reduced pressure using Rota-vap. 
The residue was weighed and the yield percentage was determined. The 
extracted plant materials were then air-dried, The extracted and air-
dried plant materials were then, placed in the Soxhlet and exhaustively 
extracted with Chloroform. The extract was filtered and evaporated 
under reduced pressure again using Rota-vap. The residue was weighed 
and the yield percentage was determined. The extracted plant materials 
were then air-dried,  
The Chloroform extracted and air-dried plant materials were then 
extracted with Methanol adopting the method described above. The 
residue was weighed and the yield percentage was determined.  
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b. Maceration 
 
The powdered plant materials (10g) were macerated separately by 
immersion for 2 hours in 3:7 water and methanol. The extracts were 
filtered and evaporated under reduced pressure using Rota-vap. The 
residue was then dried and weighed and the yield percent was obtained. 
Also, the extracted plant materials were air-dried and then weighed and 
the yield percentage was determined. 
2.2.3. Phytochemical screening 
A general screening was performed to identify the chemical constituent 
of the plants using the following method (Harbone and Baxter 1995) 
2.2.3.1.  Preparation of the extract 
Samples of the powdered part of the plants (10 grams) were refluxed 
with 100 ml of 80% ethanol in a round bottle flask for 4 hours. The cool 
solution was filtered and 80% ethanol was added to complete the filtrate 
to 100 ml. The extracts prepared were used for the identification of the 
chemical constituent of the plants. 
2.2.3.2.  Testing for the presence of Unsaturated Sterols and 
Triterpenses 
A sample (10 ml) of each extract prepered as above was evaporated to 
dryness on a water bath and the cooled residue was stirred several 
times with petroleum ether to remove most of the coloring materials. The 
residue was then extracted with 10 ml chloroform. The chloroform 
solution was dehydrated over sodium sulphate anhydrous. 5 ml portion 
of the chloroform solution was mixed with .0.5 ml of acetic anhydride 
followed by 2 drops of concentrated sulphuric acid .The gradual 
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appearance of green, blue & pink to purple colour was taken as an 
evidence for the presence of sterols (green to blue ) and Triterpenses 
(pink to purple) in the sample . 
2.2.3.3.  Testing for the presence of Alkaloids 
A sample (7.5 ml) of each extract prepared as above was evaporated to 
dryness on a water bath. 5 ml of 2N HCL was added and stirred while 
heating on the water bath for 10 minutes , and then cooled , filtered and 
divided into two test tube .To first tube few drops of Mayor's reagent 
were added to it, while to the other tube few drops of Valser's reagent 
were added to it. A slight turbidity as heavy precipitate in either of the 
two test tubes was taken as a presumptive evidence for the presence of 
alkaloids. 
2.2.3.4. Testing for the presence of Flavonoids 
A sample (7.5 ml) of extract prepared as above was evaporated in a 
water bath, cooled and the residue was defatted by several extractions 
with petroleum ether and the defatted residue was dissolved in 30 ml of 
80% ethanol and filtered. To 3 ml of the filtrate in a test tube 1 ml of 1% 
potassium hydroxide solution was added. A dark yellow color indicated 
the presence of Flavonoids compounds. 
2.2.3.5.  Testing for the presence of Tannins 
A sample (7.5 ml) of each of the extracts prepared was evaporated to 
dryness on water bath. The residue was extracted several times with N-
hexane and filtrated. The insoluble residue was stirred with 10 ml of hot 
saline solution. The mixture was cooled and filtered and the volume of 
the filtrate was adjusted to 10 ml with more saline solution. 5 ml of this 
solution was treated with few drops of gelatin salt reagent. The formation 
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of immediate precipitate was taken as evidence for the presence of 
tannin in the plant sample. To another portion of this solution, few drops 
of ferric chloride test reagent were added .The formation of blue, black 
or green colour was taken as an evidence for the presence of tannins.  
2.2.3.6. Testing for the presence of Saponins 
A sample (I g) of the original dried powdered plant material was placed in 
a clean test tube. 10 ml of distilled water was added and the tube was 
closed with a stopper and vigorously shaken for about 30 seconds .The 
tube was then allowed to stand and observed for the formation of 
honeycombs whose possible appearance for at least an hour was taken 
as an evidence for the presence of Saponins. 
2.2.3.7. Testing for the presence of Cyanogenic glycosides 
A sample (3 g) of the powdered plant was placed in an Erlenmeyer flask 
and sufficient water was added to moisten the sample, followed by 1 ml 
of chloroform (to remove every activity). A piece of freshly prepared 
sodium picrate paper was carefully inserted between a split cork which 
was used to stopper the flask , a change in color of the sodium picrate 
paper from yellow to various shades of red was taken as an indication of 
the presence of Cyanogenic glycoside . 
2.2.3.8.  Testing for the presence of Anthraquinone glycoside 
A sample (I g) of the powdered plant was boiled with 10ml of 5% ethanol 
for 5 minutes and then filtrated. The filtrate was washed with 10 ml hot 
ethanol followed by evaporation. Then 10 ml of the solution was 
extracted with 10 ml benzene, which was allowed to separate. Then the 
benzene layer was shaken with 10 ml of 10% ammonium hydroxide. The 
presence of Anthraquinone was indicated by pink and red colour. 
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2.2.4. Preparation of bacterial suspensions 
One ml aliquots of a 24 hours broth culture of the test organisms were 
aseptically distributed onto nutrient agar slopes and incubated at 37°C 
for 24 hours. The bacterial growth was harvested and washed off with 
sterile normal saline, and finally suspended in 100 ml of normal saline to 
produce a suspension containing about (l08-l09) colony forming units per 
ml using Mc Farland Scale. The suspension was stored in the refrigerator 
at 4°C until used. 
The average number of viable organisms per ml of the stock suspension 
was determined by means of the surface viable counting technique 
(Miles and Misra, 1938). Serial dilutions of the stock suspension were 
made in sterile normal saline in tubes and 0.02 ml volumes (one drop) of 
the appropriate dilutions were transferred by Transfer pipette adjustable 
volume (automatic microlitre pipette) onto the surface of dried nutrient 
agar plates. 
The plates were allowed to stand for 2 hours at room temperature for the 
drops to dry, and then incubated at 37°C for 24 hours. After incubation 
the number of developed colonies in each drop was counted. The 
average number of colonies per drop (0.02 ml) was multiplied by 50 and 
the dilution factor to give the viable count of the stock suspension 
expressed as the number of colony forming units (C.F.U.)/per ml of 
suspension. 
 Each time a fresh stock suspension was prepared; all the above 
experimental conditions were maintained so that suspensions with very 
close viable counts would be obtained. 
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2.2.5.  In vitro Testing of extracts for antimicrobial 
activity 
The cup-plate-agar diffusion method (Kavanagh, 1972) was adopted with 
some minor modifications, to assess the antibacterial activity of the 
prepared extracts. Three ml of each of the five standardised bacterial 
stock suspensions (lO8lO9 C.F.U. /ml) were thoroughly mixed with 300 ml 
of sterile melted nutrient agar which was maintained at 45°C. 
20 ml aliquots of the inoculated nutrient agar were distributed into sterile 
Petri-dishes. The agar was left to set and in each of these plates, which 
were divided to two halves, two cups in each half (10 mm in diameter) 
were cut using a sterile cork borer (No.4), each one of Petri-dishes 
halves was designed for one of the extracts. 
The agar disks were removed. Alternate cups were filled with 0.1 ml 
samples of each of the extracts using Transfer pipette adjustable volume 
(automatic microliter pipette), and allowed to diffuse at room 
temperature for 2 hours. The plates were then incubated in the upright 
position at 37°C for 18 hours. 
Two replicates were carried out for each extract against each of the test 
organisms simultaneously; (positive) controls involving the addition of 
the respective solvents instead of the extracts were carried out 
separately. After incubation the diameters of the resultant growth 
inhibition zones were measured, mean values were tabulated. 
2.2.6.  Clinical isolates 
100 clinical isolates of Staphylococcus aureus, Escherichia coli, Proteus 
vulgaris, Pseudomonas aeruginosa and Klebsiella spp were collected 
randomly from the National Health Laboratory and Khartoum Teaching 
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Hospital. The clinical isolates were obtained from wounds and 
abscesses. They were purified by streaking on plates containing the 
appropriate selective and differential culture media. They were identified 
on the basis of the results of microscopical stain reaction (Gram stain), 
cultural characteristics and biochemical tests (Cruickshank et al, 1975). 
2.2.7. Microscopical examination of aerobic 
bacterial isolates 
All isolates were subjected to microscopical examination to study their 
stain properties (using the Gram's staining technique), the shapes and 
arrangements of their cells. In principle, the bacterial film is fixed and 
stained with a Triphenylmethane dye such as Crystal violet, in 
conjunction with Iodine solution, and subsequently treated with an 
organic solvent such as Alcohol. Bacteria which retain the dye are 
identified as Gram-positive and other varieties of bacteria which lose the 
dye are identified as Gram-negative. Decolourised organisms were 
rendered visible by the application of a counter stain of suitable colour 
e.g. Safranin red. Shapes and arrangements of the cells were also 
considered. 
2.2.8. Biochemical tests 
To ensure the correct identification of the Bacteria species Biochemical 
Tests were carried out depending on the metabolic differences between 
these species. The first tests were based on the ability of the Bacterial 
species to produce acidic and gaseous end-products, when presented 
with individual carbohydrate (glucose, lactose etc...) as the sole carbon 
source. The second tests were based on determining whether the 
Bacteria species produce particular end-product such as Indole, when 
grown in suitable culture media. The third tests were carried out to 
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determine whether the Bacteria species possess certain enzymic 
activities, that synonymous with Oxidase, Urease etc... 
2.2.8.1. Fermentation tests 
Bacteria are able to ferment carbohydrates (e.g. glucose, lactose, and 
sucrose), but this process varies from species to the other. In these tests 
sterile peptone water with 1 % of the sugar was used. Phenol red as 
indicator was added and Durham tube to detect if gases were produced. 
After 24 hours incubation, the colour of the inoculated medium changed 
from pink to yellow indicating fermentation and production of acids. The 
production of gas was detected by the presence of Air-bubbles in the 
apex of the inverted Durham tube (Salle, 1961). 
2.2.8.2. Methyl-Red test 
The Methyl-Red test was used to detect the ability of some bacteria to 
produce significant amounts of acidic substances due to fermentation of 
glucose. In this test Methyl-Red Voges-Proskauer medium was used. 
After inoculation, colour changed from yellow (pH 6.2) to red (pH 4.2) 
with acid production (Cruickshank et al.1975). 
2.2.8.3.  Voges - Proskauer test 
The Voges - Proskauer test is based upon the production of Acetyl 
methyl carbinol, as a product of dextrose metabolism by certain 
bacteria. This substance is readily oxidized by atmospheric oxygen, in 
alkaline medium, giving diacetyl which, in turn, reacts with the amino 
acid Arginine in the inoculated medium to give a pink colour when alpha-
naphthol is added (Cruickshank et al, 1975). 
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2.2.8.4. Citrate utilization test 
The Citirate utilization test is based upon the ability of some organisms to 
utilize citrate as the sole carbon and energy source for growth and an 
ammonium salt as the sole source of nitrogen. In this test the Koser 
citrate medium was inoculated with a 24 hours culture of the tested 
organism and then incubated at 37°C for 2-3 days. Then when examined 
the growth changed the colour of the incorporated bromothymol blue 
indicator from green to blue, due to citrate utilizaltion and production of 
alkali (Cruickshank et al, 1975). 
2.2.8.5. Indole production test 
The Indole production test is based on the ability of certain bacteria to 
oxidize the side chain of the amino acid Tryptophane with the production 
of Indole. In this test the peptone water was inoculated with the tested 
organism, incubated for two days and when Kovac's reagent was added 
the colour changed to red, indicating the presence of Indole 
(Cruickshank et al, 1975). 
2.2.8.6.  Hydrogen Sulphide (H2S) production test 
The Hydrogen Sulphide (H2S) production test is based upon the ability of 
some bacteria to produce H2S from sulfur containing amino acids by 
reduction. H2S was tested by suspending strips of filter paper 
impregnated with lead acetate above the culture. The presence of H2S 
was demonstrated by its ability to form black insoluble lead sulfide when 
the inoculated peptone water was incubated at 37°C for 2-3 days 
(Cruickshank et al, 1975). 
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2.2.8.7.  Kligler Iron agar (K.I.A.) test 
The Kligler Iron agar (K.I.A.) test is based on the ability of some bacteria 
to ferment glucose and lactose and the production of H2S gas. The tested 
organism was inoculated and incubated at 37 °C overnight. Changing of 
the colour of the slope or butt from pink to red indicated fermentation of 
glucose (alkaline reaction), and the changing of the colour from pink to 
yellow indicated fermentation of lactose (acid reaction), (Cheesbrough, 
2000). 
2.2.8.8.  Catalase test 
The Catalase test is based on the presence of the enzyme Catalase in the 
cells of certain bacteria, whish catalyses the release of oxygen from 
hydrogen peroxide. The test was carried out by addition of few drops of 
hydrogen peroxide on a 24 hours nutrient agar culture of the tested 
organism. The production of gas bubbles indicated a positive Catalase 
reaction (Salle, 1961).  
2.2.8.9.  Coagulase test 
The Coagulase test is based on the presence of the enzyme coagulase in 
the cells of some bacteria. 1 in 10 dilution of citrated human plasma in 
saline was added to few drops of inoculated broth culture with the tested 
organism, and then the mixture was incubated at 37°C. The mixture was 
examined for coagulation after 1, 3 and 6 hours. The formation of clearly 
visible clots indicated a positive coagulase test (Cruickshank el al, 1975). 
2.2.8.10.  Oxidase test 
The Oxidase test is based on the presence of the enzyme Oxidase in the 
cells of certain bacteria, which catalyzes the transport of electrons 
between electron donors in the bacteria and Tetramethyl-p-
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phenylenediamine dihydrochloride. A freshly prepared oxidase reagent 
when added in a solid growth medium, a purple colour rapidly developed 
at the colonies of oxidase positive organisms (Cruickshank et al, 1975; 
Salle, 1961). 
2.2.8.11.  Urease test 
The Urease test is based on the presence of the enzyme Urease in the 
cells of certain bacteria. Urease enzyme catalyzes the decomposition of 
urea and the production of ammonia. The test was carried out by 
growing the tested organism in presence of urea. Ammonia production 
was tested by means of suitable pH indicator e.g. phenol red. When 
colour changed from yellow to pink and ammonia produced a positive 
test was indicated (Salle, 1961). 
2.2.8.12.  Deoxyribonuclease (DNase) test 
The Deoxyribonuclease (DNase) test is based on the ability of 
Staphylococcus aureus in producing the enzyme Deoxy ribonuclease 
(DNase). The tested organism was cultured on a medium which 
contained (DNA). After overnight incubation, the colonies were tested for 
DNase production by flooding the plate with a (IN) HCl acid solution. The 
acid precipitated unhydrolysed DNA. DNase producing colonies were 
therefore surrounded by clear areas indicating DNA hydrolysis 
(Cheesbrough, 1996). 
2.2.9. Testing the susceptibility of clinical isolates to 
herbal extracts 
The standard cup plate agar diffusion technique was used to determine 
the susceptibility of the clinical strains to the various extracts which 
showed activity against standard bacterial organisms. 
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2.2.9.1. Determination of minimum inhibitory concentration 
(MIC) by agar plate dilution method 
The principle of the agar plate dilution method is testing the inhibition of 
the growth of the seeded bacteria on the surface of the agar by the 
incorporated plant extracts. Plates were prepared by adding a series of 
increasing concentrations of the plant extract to the media, in the 
following order: 3.125, 6.25, 12.5, 25, 50 and 100 mg/ml. The bottom of 
each plate was marked into five segments to test the standard bacteria. 
The organism to be tested was grown in broth over-night, and then 
diluted in broth to contain about 10 cells per ml. A loop-ful of the diluted 
culture is spotted with standard-loop that delivers 0.01 ml onto the 
surface of each segment and then incubated at 37°C for 18 hours. 
2.2.9.2.  Reading of (MIC) plates 
The Minimum Inhibitory Concentration (MIC) is the least concentration of 
any antimicrobial agent that completely inhibits bacterial growth. Results 
are reported as the MIC in mg/ml of crude extract. 
2.2.10.  Antibacterial activity of commonly used 
antibiotics against standard organisms 
Four Antibiotics (Benzylpenicillin, Gentamycin, Ceftriaxone and 
Erythromycin) were prepared in suspensions of four concentrations (40, 
20, 10 and 5 µg/ml) using sterile distilled water; to evaluate their 
antibacterial activity against the tested standard bacterial organisms, 
using the cup plate agar diffusion method described above. 
Removed cups were filled with 0.1 ml samples of each of the four 
concentrations of the reference drugs using Transfer pipette adjustable 
volume automatic microtitre pipette, and allowed to diffuse at room 
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temperature for two hours. The plates were then incubated in the upright 
position at 37°C for 18 hours. 
Two replicates were carried out for each concentration against each of 
the test organisms simultaneously. After incubation the diameters of the 
resultant growth inhibition zones were measured, averaged and the 
mean values were tabulated. 
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3. Results  
 
3.1. Identification of Clinical Bacterial Organisms  
Standard and clinical bacterial organisms were used to evaluate their 
susceptibility to four standard chemotherapeutic agents. As shown in 
table 5, the standard bacterial organisms were obtained from the 
National Collection of Type Culture (NCTC), Colindale, England and the 
American Type Culture Collection (ATCC), Rockville, Maryland, USA.  
The clinical bacterial organisms were isolated from swaps taken from 
wounds and abscesses. A total of 100 isolates were randomly taken and 
they were found to consist of 20, 20, 18, 17, 18 and 7 of Escherichia coli; 
Pseudomonas aeruginosa; Proteus vulgaris; Klebseilla sp.; 
Staphylococcus aureus; and Methicillin-resistant Staphylococcus aureus 
(MRSA) isolates respectively. These bacterial species were identified 
adopting the standard methods. 
. 
3.1.1. Identification of Escherichia coli 
 
A. Cultural characteristics 
After 24 hours incubation of the cultured Mac Conkey's agar medium, 
red colonies were observed, this was attributed to lactose fermentation. 
This Cultural characteristic is synonyms with Escherichia coli. However, 
to confirm this result, more tests were carried out.  
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B. Microscopical examination 
The bacterial isolates were subjected to microscopical examination 
using the Gram's staining technique (Cruickshank et al, 1975), Gram 
negative rods were seen. This result is a further confirmation that the 
bacterium earlier identified was Escherichia coli. For conclusiveness 
biochemical reaction tests were carried out and the results are given 
below.  
C. Biochemical reactions 
The bacterial isolates were subjected to biochemical reaction tests. The 
bacterium was identified as Escherichia coli, hence confirming the 
results obtained adopting the above two tests. The bacterium 
identification was based on the following results: 
1. The fermentation test, described in section 2.2.4.3.1, showed that all 
isolates fermented lactose, manitol and glucose and produced acid 
and gas, and most of them fermented sucrose and produced acid and 
gas (Salle, 1961). 
2. The Methyl Red positive test, described in section 2.2.4.3.1, gave 
positive results for all isolates which fermented glucose and 
produced acid (Cruickshank et al, 1975). 
3. The Voges Proskauer test, described in section 2.2.4.3.3, gave 
negative results for all isolates that did not metabolize dextrose, and 
Acetyl methyl carbinol was not produced (Cruickshank et al, 1975). 
4. Indole production test, described in section 2.2.4.3.3, showed that all 
isolates oxidised the side chain of the amino acid Tryptophane and 
produced Indole (Cruickshank et al, 1975).  
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5. Citrate utilization test, described in section 2.2.4.3.4, showed that 
none of the tested isolates utilized citrate (Cruickshank et al, 1975). 
6. The Oxidase test, as described in section 2.2.4.3.10, no purple colour 
was developed, indicating negative results (Cruickshank et al, 1975; 
Salle, 1961). 
7. The Urease test, as described in section 2.2.4.3.11 the yellow colour 
didn’t change to pink indicating that there was no ammonia produced, 
which was a negative result (Salle, 1961) 
8. Kligler Iron agar (K.I.A.) test, described in section 2.2.4.3.7,  showed 
that all isolates did not change the yellow colour of K.I.A. neither in 
slope nor in butt, with the absence of H2S production, however all the 
tested isolates produced gas (Cheesbrough, 2000). 
3.1.2. Identification of Proteus vulgaris  
A. Cultural characteristics 
After 24 hours incubation of the cultured Nutrient agar, a fishy smell was 
detected and swarming appearance was seen. Whereas on the cultured 
Mac Conkey's agar medium, pale coloured colonies were observed 
indicative of non-lactose fermentation. These Cultural characteristics 
are synonyms with Proteus vulgaris. However, to confirm this result, 
more tests were carried out.  
B. Microscopical examination 
The bacterial isolates were subjected to microscopical examination 
using the Gram's staining technique (Cruickshank et al, 1975), where 
Gram negative rods were seen. This further confirmed that the 
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bacterium was Proteus vulgaris. However, biochemical reaction tests 
were carried out to corroborate these results.  
C. Biochemical reactions 
The bacterial isolates were subjected to biochemical reaction tests. The 
bacterium was identified as Proteus vulgaris, hence confirming the 
results obtained from the above described tests. The bacterium 
identification was based on the following results: 
1. The fermentation test described in section 2.2.4.3.1 showed that not 
all isolates fermented lactose, and most of them did not ferment 
mannitol or sucrose and none produced acid; however, some of them 
formed gas (Salle, 1961). 
2. The Methyl Red positive test described in section 2.2.4.3.1 gave 
positive results for all the isolates; they fermented glucose and 
produced acid (Cruickshank et al, 1975). 
3. The Voges Proskauer test described in section 2.2.4.3.3 gave 
negative results for all the tested isolates, they didn’t metabolise 
dextrose and Acetyl methyl carbinol was not produced (Cruickshank 
et al, 1975). 
4. The Indole production test described in section 2.2.4.3.3 showed that 
all the isolates oxidised the side chain of the amino acid Tryptophane 
and Indole was produced (Cruickshank et al, 1975).  
5. The Citirate utilization test described in section 2.2.4.3.4 showed that 
the isolates utilized citrate (Cruickshank et al, 1975).  
6. The Oxidase test, as described in section 2.2.4.3.10, no purple colour 
was developed indicating negative results (Cruickshank et al, 1975; 
Salle, 1961). 
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7. The Urease test, as described in section 2.2.4.3.11 the yellow colour 
changed to pink as a results of ammonia production indicating 
positive results (Salle, 1961; Cruickshank et al, 1975). 
8. The Kligler Iron agar (K.I.A.) test described in section 2.2.4.3.7 
showed that all the isolates changed the yellow colour of K.I.A. to red 
in slope and no change of colour in the butt, H2S was produced, but no 
gas was produced (Cheesbrough, 2000). 
3.1.3. Identification of Pseudomonas 
aeruginosa  
A. Cultural characteristics 
After 24 hours incubation of the cultured Nutrient agar, blue-green 
pigments was produced and diffused in the surrounding media. These 
Cultural characteristics are synonyms with Pseudomonas aeruginosa. 
However, to confirm this result, more tests were carried out.  
B. Microscopical examination 
The bacterial isolates were subjected to microscopical examination 
using the Gram's staining technique, and Gram negative rods were seen. 
This further confirmed that the bacterium was Pseudomonas aeruginosa. 
However, for more confirmation, biochemical reaction tests were carried 
out.  
C. Biochemical reactions 
The bacterial isolates were subjected to biochemical reaction tests. The 
bacterium was identified as Pseudomonas aeruginosa hence confirming 
the results obtained from the above two tests. The bacterium 
identification was based on the following results: 
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1. The fermentation test described in section 2.2.4.3.1 showed that all 
isolates did not ferment lactose, and most of them fermented glucose 
and did not ferment sucrose (Salle, 1961). 
2. The Methyl Red positive test described in section 2.2.4.3.1 gave 
negative results for all isolates which didn’t ferment glucose and 
didn’t produce acid Cruickshank et al, 1975). 
3. The Voges Proskauer test described in section 2.2.4.3.3 gave 
negative results for all isolates which didn’t metabolise dextrose and 
Acetyl methyl carbinol was not produced Cruickshank et al, 1975). 
4. Indole production test described in section 2.2.4.3.3 showed that all 
isolates didn’t oxidise the side chain of the amino acid Tryptophane 
and didn’t produce Indole Cruickshank et al, 1975).  
5. The Citrate utilization test described in section 2.2.4.3.4 showed that 
the isolates didn’t utilize citrate indicating negative results 
(Cruickshasnk et al, 1975). 
6. The Oxidase test, as described in section 2.2.4.3.10, a purple colour 
was developed indicating postive results (Cruickshank et al, 1975; 
Salle, 1961). 
7. The Urease test, as described in section 2.2.4.3.11 the yellow colour 
changed to pink as a results of ammonia production indicating 
positive results (Salle, 1961; Cruickshank et al, 1975). 
8. The Kligler Iron agar (K.I.A.) test described in section 2.2.4.3.7 
showed that all isolates changed the yellow colour of K.I.A. to red in 
slope and most of the isolates changed of colour to red in the butt, no 
H2S or gas was produced (Cheesbrough, 2000). 
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9. The Oxidase test described in section 2.1.8.10 showed that when 
oxidase reagent was added in the solid growth medium, a purple 
colour was rapidly developed indicating positive oxidase production 
(Cruickshank et al, 1975; Salle, 1961). 
3.1.4. Identification of Stapliylococcus aureus  
A. Cultural characteristics 
After 24 hours incubation of the cultured Nutrient agar, golden yellow 
colonies were observed. On Mannitol salt agar, the colour of medium 
changed from red to yellow These Cultural characteristics are synonyms 
with Stapliylococcus aureus. However, to confirm this result, additional 
tests were carried out.  
B. Microscopical examination 
The bacterial isolates were subjected to microscopical examination 
using the Gram's staining technique, and Gram positive cocci arranged 
in grape-like clusters were seen. This further confirmed that the 
bacterium was Stapliylococcus aureus. However, for more confirmation, 
various biochemical reaction tests were carried out (Cruickshank et al, 
1975).  
C. Biochemical reactions 
The bacterial isolates were subjected to biochemical reaction tests. The 
bacterium was identified as Stapliylococcus aureus hence confirming 
the results obtained from the above two tests. The bacterium 
identification was based on the following results: 
1. The fermentation test described in section 2.2.4.3.1 showed that all 
isolates fermented lactose and produced acid and no gas, and they 
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fermented sucrose and mannitol and produced acid. Most of the 
isolates fermented glucose and produced acid (Salle, 1961). 
2. The Catalase test described in section 2.2.4.3.8 showed that all 
isolates were catalase positive. They catalysed the release of oxygen 
from hydrogen peroxide, where gas bubbles were observed 
(Cruickshank et al, 1975).  
3. The Coagulase test described in section 2.2.9.9 showed that all 
isolates were coagulase positive; visible clots were formed indicating 
the presence of the enzyme coagulase (Cruickshank et al, 1975). 
4. The Deoxyribonuclease (DNase) test described in section 2.2.9.12 
showed that all isolates were DNase positive. It was observed that 
DNase producing colonies were surrounded by clear areas indicating 
DNA hydrolysis because of adding HCL acid to the cultured medium 
that contained DNA (Cheesbrough, 1996). 
3.1.5. Identification of Klebsiella sp 
A. Cultural characteristics 
After 24 hours incubation of the cultured Nutrient agar, golden yellow 
colonies were observed. On Mannitol salt agar, the colour of medium 
changed from red to yellow. These Cultural characteristics are 
synonyms with Klebsella sp. However, to confirm this result, more tests 
were carried out.  
B. Microscopical examination 
The bacterial isolates were subjected to microscopical examination 
using the Gram's staining technique, and Gram negative capsulated rods 
were seen. This further confirmed that the bacterium was Klebsella sp. 
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However, for more confirmation, biochemical reaction tests were carried 
out (Cruickshank et al, 1975).  
 
C. Biochemical reactions 
The bacterial isolates were subjected to biochemical reaction tests. The 
bacterium was identified as Klebsella sp, hence confirming the results 
obtained from the above two tests. The bacterium identification was 
based on the following results: 
1. The fermentation test described in section 2.2.4.3.1 showed that all 
isolates fermented lactose, sucrose and manitol and produced gas 
(Salle, 1961). 
2. The Citrate utilization test described in section 2.2.4.3.4 showed that 
the isolates utilized citrate indicating posative results (Cruickshasnk 
et al, 1975). 
3. The Oxidase test, as described in section 2.2.4.3.10, no purple colour 
was developed indicating negative results (Cruickshank et al, 1975; 
Salle, 1961). 
4. The Urease test, as described in section 2.2.4.3.11 the yellow colour 
changed to pink as a results of ammonia production indicating 
positive results (Salle, 1961; Cruickshank et al, 1975). 
5. The Catalase test described in section 2.2.4.3.8 gas bubbles were 
seen due to oxygen production indicating posative results. (Salle, 
1961). 
The results of the clinical bacterial organisms’ identification were shown 
in table 6. 
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3.2. Medicinal plants phytochemical screening 
Phytochemical analysis for major phytoconstituents of the plant extracts 
was undertaken using standard qualitative methods as described in 
section 2.2.3 which were based on methods adopted by various authors 
(Vogel, 1958; Kapoor et al., 1969; Rizk and Bashir, 1980; Fadeyi et al., 
1989; Odebiyi and Sofowora, 1990). The medicinal plants extracts were 
screened for the presence of biologically active compounds like 
glycosides, phenolics, alkaloids, tannins, flavonoids, saponins and 
steroids. The results obtained are discussed and tabulated (Table 8) 
below. 
Phytochemical analysis showed that:  
1. Piper cubeba extract contains Tannins, Flavonoids, Cardiac 
glycoside, phenolic glycoside, and Alkaloids. 
2. Anogussus leiocapus contains Tannins, Saponins, phenolic glycoside, 
Alkaloids and only traces of Anthraquinone glycoside and Cyanogenic 
glycosides. 
3. Biota orientalis extract contains Saponins, Tannins, Alkaloids and 
only traces of Cardic glycoside. 
4. Punica granatum (Bark) extract contains Saponins, Tannins, 
Anthraquinone glycoside, Alkaloids and only traces of Cardic 
glycoside, phenolic glycoside. 
5.  Punica granatum (Wood) extract contains Saponins, Tannins, 
Anthraquinone glycoside, Alkaloids, Cardic glycoside and phenolic 
glycoside. 
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6. Calendula arvensis extract contains Tannins, Flavonoids and only 
traces of Anthraquinone glycoside. 
7. Salvia officinalis extract contains Tannins, Anthraquinone glycoside, 
Cardic glycoside and Alkaloids. 
8. Nauclia latifolia extract contains Flavonoids, phenolic glycoside, 
Alkaloids. 
9. Cissus petiolata extract contains Saponins, Flavonoids, phenolic 
glycoside, Cyanogenic glycosides. 
10. Petasties hybriduss L. extract contains Saponins, Tannins, 
Flavonoids, phenolic glycoside, Alkaloids. 
11. Acorus calamus extract contains Saponins, Flavonoids, Cardic 
glycoside, Alkaloids. 
12. Ferula asafoetida extract contains Flavonoids only traces of 
phenolic glycoside, Cyanogenic glycosides. 
13. Moringa peregrina extract contains Saponins, Flavonoids, 
Cyanogenic glycosides, Alkaloids. 
3.3. Susceptibility of standard bacteria to 
standard chemotherapeutic agents 
The antimicrobial activity of the four conventional chemotherapeutic 
agents against five standard bacterial organisms was determined. The 
chemotherapeutic agents which are currently in use worldwide are 
Benzylepenicillin, Erythromycin, Gentamycin and Ceftriaxone. Varying 
concentrations (40, 20, 10 and 5 µg/ml) of these agents were used in the 
investigations. The standard bacterial organisms tested were 
Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginos, 
 Page 106 of 219 
 
Table 8: Chemical constituent of the 13 medicinal plants 
 
 
1: Saponins, 2: Tannins ; 3:  Anthraquinone glycoside ; 4: Flavonoids ; 5 : Cardic glycoside ; 6 : Phenolic gycoside ; 7 : 
Cyanogenic glycosides ; 8 : Alkaloids.(+) : positive ;  (-) : negative ; (±) : Traces 
Klebsiella sp and Bacillus subtilis (Table 5). The potency of the four 
antibiotics was assessed by the presence or absence of inhibition zone 
and zone diameter, respectively. The results in terms of averages of 
inhibition zones are given in Table 9. The commonly used terms: 
resistant and sensitive were adopted in this study to interpret the results 
obtained. 
Latin name Arabic name 
Yield% of 
MeOH 
extract 
Phytochemical groups 
1 2 3 4 5 6 7 8 
Piper cubeba سوﺮﻌﻟا ﺐﺣ 2.13 - + - + + + - +
Anogussus leiocapus ﺐﺤﺼﻟا 1.3 + + ± - - + ± +
BIota (Thuja) orientalis  ﺔﺼﻔﻌﻟا 0.74 + + - - ± - - +
Punica granatum  (Bark)   نﺎﻣﺮﻟا 3.8 + + + - ± ± - +
Punica granatum  (Wood)  نﺎﻣﺮﻟا 2.7 + + + - + + - +
Calendula arvensis ﻩﻮﻨﺤﻟا 2.45 - + ± + - - - - 
Salvia officinalis ﺔﻴﻤﻳﺮﻣ 0.84 - + + - + - - +
Nauclia latifolia ةدوﺪﻣﺮآ 3.12 - - - + - + - +
Cissus petiolata ﺮﺠﺤﻟا قﺮﻋ 3.14 + - - + - + + - 
Petasties hybriduss  ﺖﻬﻜﻓ 2.22 + + - + - + - +
Acorus calamus  ﺮﻳ رﺬﻟاﻩ 0.24 + - - + + - - +
Ferula asafoetida ﻠﺤﻟاﺘﺖﻴ 1.14 - - - + - ± ± - 
Moringa perigrina  قاواﺮﻟا 5.34 + - - + - - + +
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The aim of this part of the study was to compare the antimicrobial activity 
of the four standard chemotherapeutic agents which was determined in 
this part of the study to the antimicrobial activity of the same agents and 
the 12 medicinal plants extracts when tested against clinical bacterial 
organisms (section 3.4).  
The results (Tables 9 and 10 and Figures 1 and 2) show that the 
antibacterial efficacy of the four standard chemotherapeutic agents 
follows the ascending order: Benzylepenicillin, Erythromycin > 
Gentamycin > Ceftriaxone. It was found that there was significant 
differences between the four standard chemotherapeutic agents in 
terms of their antibacterial effectiveness against the test standard 
bacteria. From Table 9 it could be seen that compared to the other 
agents, Benzylepenicillin is the least effective, it showed no antibacterial 
effect against all test bacterial strains. The results also, showed that the 
Erythromycin when tested at the four concentrations used, showed low 
antibacterial activity. It was active only against Staphylococcus aureus. 
Whereas, Ceftriaxone showed the highest antibacterial effectiveness, at 
the four tested concentrations, it inhibited the growth of all test bacterial 
organisms at varying levels, except Klebsiella sp. Gentamycin was the 
second effective antibacterial agent; at all the concentrations, it 
inhibited the growth of all test bacterial organisms except Pseudomonas 
aeruginosa when tested at the two lowest concentrations (10 and 5 
µg/ml). In general, it was observed that the inhibition level varies 
according to the bacterial species and the antibiotic and its 
concentration.   
The results in Table 9 and 10 and Figures 1- 5 show that the susceptibility 
of the test bacteria follows the ascending order: Klebsiella sp> 
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Pseudomonas aeruginosa > Bacillus subtilis > Escherichia coli > 
Staphylococcus aureus. The results also, showed significant differences 
between the five standard bacterial organisms in terms of their 
susceptibility to the standard chemotherapeutic agents. 
Table 9: Antibacterial Activity of Chemotherapeutic 
 Agents against Standard Bacterial Organisims 
 
Chemotherapeutic 
Agents 
Concentration 
µg/ml 
MIZD(mm) 
Ec Sa Ps a Kl Bs 
Benzylepenicillin 40 
20 
10 
5 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Erythromycin  40 
20 
10 
5 
0 
0 
0 
0 
30 
25 
20 
10 
0 
0 
0 
0 
0 
0 
0 
0 
35 
30 
25 
40 
Gentamycin 40 
20 
10 
5 
25 
20 
15 
15 
24 
20 
18 
15 
15 
15 
0 
0 
25 
25 
25 
25 
29 
25 
22 
20 
Ceftriaxone 40 
20 
10 
5 
36 
30 
25 
23 
35 
29 
24 
24 
32 
30 
22 
20 
0 
0 
0 
0 
19 
17 
13 
12 
 
Standard Organisms used: Ec: Escherichia coli; Sa: Staphylococcus aureus; Ps a: Pseudomonas 
aeruginosa; Kl: Klebsella sp; Bs: Bacillus subtilis. 
MIZD (mm): Mean Inhibition Zone Diameter (>15mm: Sensitive; 14-15: Intermediate;  
< 14: Resistant; 0: No inhibition). 
 
According to the results shown in Table 9, the least susceptible 
bacterium was Klebsella sp. it has shown susceptibility to none of the 
tested antibiotics except Gentamycin.  Bacillus subtilis showed 
susceptibility to Gentamycin at all tested concentrations (40, 20, 10 and 
5 µg/ml) and to Ceftriaxone at the two highest concentrations (40 and 20 
µg/ml).  The results also, showed that Staphylococcus aureus was the 
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most susceptible to antibiotics; it has shown susceptibility to all tested 
antibiotics except Benzylepenicillin. Both Bacillus subtilis and 
Escherichia coli showed moderate susceptibility to antibiotics, they 
showed susceptibility to just two of the tested antibiotics (Gentamycin 
and Ceftriaxone). The differences in the level of susceptibility are most 
likely due to the mode and site of action of the chemotherapeutic agents. 
Figure 1: Antibacterial Activity of Chemotherapeutic Agents against 
Standard Staphylococcus aureus 
 
 
 
MIZD (mm): Mean Inhibition Zone Diameter (>15mm: Sensitive; 14-15: Intermediate;  
< 14: Resistant; 0: No inhibition). 
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